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Cardiac Resynchronization Therapy (CRT) reduces morbidity and mortality in patients with heart 
failure and electrical dyssynchrony. 1-7 Recommendations for which patients should receive a 
CRT device are outlined in cardiology society guidelines. However, these recommendations vary 
and for certain recommendations are imprecise. The purpose of this PhD is to explore why there 
are variations in international guideline recommendations and how these may contribute to 
differences in practice using the cohort of CRT Survey II with 11 088 patients in 42 European 
Society of Cardiology (ESC) member countries.  
Methods 
The recommendations provided by the major international guidelines were reviewed to identify 
areas of consistency and inconsistency in CRT recommendations. Data were collected on 
consecutive patients implanted with a CRT device in 42 ESC countries. These data were analysed 
to assess CRT practice and guideline adherence and relate them to variations in guideline 
recommendations.  
Results 
There was mainly consistency in the international guidelines regarding who should receive a 
device. However, some inconsistencies were identified. These included patients with non-left 
bundle branch block (LBBB) and patients with heart failure and a pacemaker requirement, 
implanted with a CRT to avoid right ventricular pacing dependence. Some of these 
inconsistencies could be explained by the timing of the release of the guidelines. However, others 
appeared to be related to CRT trial evidence being interpreted differently by different societies. In 
the European CRT population we found that implanters adhered well to European guidelines with 
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only 2% of patients being implanted outside guideline recommendations. However, practice did 
vary in the different countries and these variations were more pronounced in areas where 
guideline recommendations are inconsistent or undetermined.  
Discussion 
Adherence to guidelines for CRT in Europe is high. However, in areas where there is limited 
CRT trial evidence this results in imprecise and inconsistent recommendations in international 



















1.1 Heart Failure and Electrical Dyssynchrony 
 
Heart failure (HF) is a complex clinical syndrome characterized by symptoms and signs includ ing 
breathlessness, fatigue and fluid retention. It is associated with increased hospitalization and 
mortality rates. The principal treatment for heart failure is pharmacological.  8  
 
A common finding in heart failure patients is that their left ventricle (LV) is dilated and their heart 
pumps ineffectively. 9 These patients are described as having heart failure due to reduced ejection 
fraction (HFrEF) or systolic heart failure. Certain patients with systolic heart failure also show 
signs of electrical dyssynchrony on their electrocardiogram (ECG) exhibited by a prolonged QRS 
duration.  This prolongation of the QRS duration is due to disruption of the normal electrical 
conduction system due to myocardial damage caused by ischaemia or cardiomyopathy. 10 This 
disruption leads to abnormal ventricular depolarization and dyssynchronous ventricular systolic 
contraction. This dyssynchrony results in a reduction in the efficiency of cardiac contractile forces , 
which further aggravates the systolic dysfunction.  10 Cardiac resynchronization therapy (CRT) is 








1.2 Cardiac Resynchronization Therapy  
A CRT device has an additional lead compared with a traditional two-lead pacemaker. This third 
lead, shown in figure 1, is placed on the left ventricle via a cardiac vein and acts with the right 
ventricle (RV) lead to enable biventricular pacing.  Such pacing improves the synchrony of 
ventricular contraction in patients with a prolonged QRS duration. 10 CRT has been shown in 
large randomized control trials (RCT) to decrease both morbidity and mortality.  1-7  
Figure 1 – Cardiac Resynchronization Therapy  
 
 







1.3 CRT Guideline Recommendations  
Optimal medical treatment for heart failure is detailed in the various guidelines produced by 
international cardiology societies. The task forces producing the guidelines review the current 
evidence available including randomised controlled trials and meta-analysis of such trials and use 
these to provide recommendations for treatment. These recommendations are supplemented by 
information on the quality of the evidence behind these guidelines. Table 1 and 2 show how the 
European Society of Cardiology (ESC) present their recommendations and evidence levels. Other 
international societies use similar schemes. 8 
 












However, despite the fact that the guideline task forces review the same evidence, their guideline 
recommendations occasionally differ. 11 
 
1.4 The Evidence for CRT and Evolution of European Guidelines  
The initial pivotal CRT RCTs from 2001 and 2002 showed improved exercise tolerance and 
quality of life in patients receiving this therapy. 1, 2 From 2004 CRT was shown to improve not 
only morbidity, but also mortality of patients with severe heart failure and left ventricular 
dysfunction. 3, 7 In that year, the first ESC guidelines to recommend CRT for the use in heart 
failure were published. They provided a recommendation class I (is recommended), evidence 
level A for patients with reduced ejection fraction (EF) and QRS duration ≥ 120 ms in  New York 
Heart Association (NYHA) functional class III –IV. 12  These were mirrored by the 2007 ESC 
Guidelines for Cardiac Pacing and Cardiac Resynchronization Therapy.13 These guidelines also 
introduced other patient groups who might benefit from CRT, including patients with atrial 
fibrillation and patients with low ejection fraction, heart failure and a concomitant indication for 
16 
 
permanent pacing. However, due to the limited evidence available for these indications, they 
were only awarded a recommendation class IIa (should be considered) and the lowest evidence 
level C. 13 These guidelines also introduced the idea that patients with overlapping indications for 
a CRT and an Implantable Cardioverter Defibrillator (ICD) should be implanted with a CRT-D 
device. (class I recommendation, evidence level B).  
 
Following the publication of the REVERSE, MADIT-CRT and RAFT CRT trials demonstrating 
morbidity and mortality benefits also in those patients with less symptoms of heart failure, the 
2010 focus update of ESC guidelines expanded their recommendation class I for patients with 
reduced ejection fraction and QRS ≥ 120 ms to include NYHA Class II patients. 4-6, 14 
 
The observation that patients with left bundle branch block (LBBB) appear to better respond to 
CRT than those without LBBB came from subgroup analysis of the REVERSE and MADIT-CRT 
trials.  15, 16 Although the 2010 ESC focused update stated that the evidence was strongest for 
patients with a LBBB pattern, a lower recommendation class was not provided for patients with 
non-LBBB until the 2012 ESC guidelines on the diagnosis and treatment of acute and chronic 
heart failure. 14 17  
 
In 2013 the results of Echo CRT were published and showed that CRT did not reduce 
hospitalization rates or mortality for patients with a QRS duration <130 ms and may actually be 
increasing mortality in this heart failure population. 18 This lead the task force of the ESC HFA 
Guidelines for Treatment of Acute and Chronic Heart Failure of 2016 to raise the lower 
recommendation class for CRT implantation to 130 ms.  8 These same guidelines were also 
influenced by the result of the BLOCK HF trial, which showed that patients with systolic heart 
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failure, reduced LVEF and a high degree AV block had greater mortality with a traditional two 
lead pacemaker compared with a CRT. 19 This patient group was awarded a recommendation 
class I evidence level A for CRT.  8 
 
1.5 CRT-P vs. CRT-D  
CRT devices can be implanted with a pacemaker component (CRT-P) or with a pacemaker and a 
defibrillator component (CRT-D). Implanting the defibrillator lead of the CRT-D results in a 
slightly greater risk of complications during implantation. A CRT-D device has also a slightly 
higher cost than a CRT-P device.20 However, most patients with heart failure who qualify for a 
CRT device also have an overlapping indication for an ICD due to their increased risk of sudden 
cardiac death. 8 For patients with a wide QRS complex the decision to implant a CRT-P vs.  
CRT-D is challenging as no randomized study has been powered to compare CRT-P vs. CRT-D.  
As a consequence, limited advice is provided by international guidelines on choice of device 
type. 11   
 
1.6 Surveys and Registries  
RCTs provide the evidence for heart failure treatment, however they have strict inclusion and 
exclusion criteria, thereby limiting the inclusion of elderly patients and patients with 
comorbidities. 21. It is estimated that less than one third of patients >65 years of age with heart 
failure would quality for inclusion in a RCT. 22 Registries and surveys on the other hand include a 
wide range of patients and thereby more accurately describe clinical practice 23 Despite their 
limitation of being prone to bias, they provide an opportunity to assess guideline implementation 
and adherence. Information on guideline adherence can therefore be fed back to guideline task 
forces.  24, 25 
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Good adherence to guideline-directed pharmacological treatment has been shown to be associated 
with improved patient prognosis. 26 However, there is limited research on adherence to device 
therapy guidelines and published studies include few patients. 
 
1.7 CRT Survey II  
CRT Survey II is a 15-month survey of CRT practice in ESC member countries. CRT implanters 
across Europe were asked to enter data related to CRT implantation for consecutive patients 
implanted with a CRT device in 2015-2016 for both successful and unsuccessful implantations. 
These devices included both upgrades from a previous device (ICD or pacemaker) and de novo 
devices. Data on both CRT-P and CRT-D implantation was collected. CRT Survey II collected 
data on 11088 patients in 42 countries. It represents the largest survey of CRT practice in Europe 
and thereby provides an opportunity to assess clinical practice and guideline adherence in ESC 
member countries.  
 
1.8 Overall Aim of the Thesis  
This PhD thesis explores how evidence on CRT is interpreted by international guideline task 
forces. It examines how these guidelines are applied in clinical practice, including when 
guidelines provide inconsistent recommendations and how this effects clinical practice.  
 
It specifically:  
 Describes clinical practice in ESC member states 




 Specifically addresses choice of device type, CRT-P vs. CRT-D – an area where there 



















2.1 Paper 1 - Guideline Comparison 
The most recent international guidelines on CRT were identified using the databases 
MEDLINE and EMBASE. Focused searches were conducted using both keyword search and 
free text search. Search terms included: guideline, ‘cardiac resynchronisation therapy, 
cardiac resynchroniza t ion therapy, CRT and heart failure. Each guideline was then 
thoroughly reviewed and the various recommendations compared and contrasted with the 
other CRT guidelines. Explanations for inconsistencies in the guidelines were sought by 
relating the guideline recommendation to the timing of the guideline publication and to the 
relevant evidence available at that time.  
2.2 Paper 2, 3 and 4 - CRT Survey II 
2.2.1 Design and Objectives of CRT Survey II 
CRT Survey II was designed as a joint initiative between the two ESC associations EHRA and 
HFA to capture information regarding current clinical practice for CRT. A scientific committee 
(SC) was established including members of each association together with representatives from 
all five major device companies. The role of the SC was to decide on data points for collection, 
to develop the statistical analysis plan (SAP) and to contribute to the publication process.  
2.2.2 Patient Recruitment and Data Collection   
A national coordinator (NC) for each country was nominated by the head of the respective 
national arrhythmia societies. The NC was responsible for recruiting centres for participation in 
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the survey.  Centres were requested to provide data on consecutive patients implanted with either 
a CRT-P or a CRT-D, whether the device was de-novo or an upgrade from a previous device.  
Battery changes were excluded. Data was collected on patients implanted with a CRT device 
between 1st of October 2015 and 31st of December 2016.  
 
The data were entered using an online electronic case report form (eCRF).  The implanter 
completed an eCRF for each patient, whether the CRT procedure was successful or unsuccessful. 
The data were stored and managed by our data management company Institut für 
Herzinfarktforschung (IHF) based in Ludwigshafen, Germany.   
 
Each implanter was also asked to complete a one-time site questionnaire detailing the 
demographics and facilities available at each implanting centre. The details of the eCRF and the 
one-time site questionnaire are included in appendix 1 and 2 respectively.  
 
2.2.3 Statistical Analysis  
All data analyses were performed using SAS®, release 9.3 and 9.4 (SAS Institute Inc., Cary, NC, 
USA) on a Microsoft® Windows® 7 and 10 Enterprise platform. All percentages were relative to 
the total number of patients with available information. The medians were reported with 
interquartile ranges (IQR). P-values were calculated using Mann-Whitney-Wilcoxon test when 
comparing medians and Chi²-Test when comparing percentages. Missing values were not 
imputed. Regression analyses were performed for paper 3 and 4 based on multivariate analysis. 
Factors postulated to be associated with implantation of a CRT-P (paper 3) or influencing the 
recommendation class supporting implantation (paper 4) were made binomial and included in a 
22 
 
multiple regression analysis with a probability model. Odds ratios (OR) for implantation with a 
CRT-P vs. CRT-D (paper 3) or under class I vs. non-class I (paper 4) indications were calculated. 
The Hosmer and Lemeshow test for goodness of fit was used to test the validity of the regression 
model.  
 
2.2.4 Ethical Considerations  
We took great care in designing the eCRF to ensure that it was completely anonymized. It was 
approved by ESC data experts and deemed to be completely anonymized. The patients were not 
followed up after hospitalization. The lack of follow-up after hospitalization and the anonymized 
nature of the data collected obviated the need for Institutional Review Board (IRB) approval in 
most countries. However, in order to participate in the survey, countries had to provide proof that 
they had either informed their local IRB about the survey and did not require formal approval or 












3.1 Paper 1 – Indications for Cardiac Resynchronization Therapy: A Comparison of the Major 
International Guidelines. 
This paper summarizes the most recent international guideline recommendations for CRT and 
their corresponding levels of evidence. Overall, there is great consensus in the guidelines with 
equal recommendation classes and evidence levels for CRT implantation in the various groups. 
For CRT in patient groups with the strongest evidence base, such as those with sinus rhythm, 
QRS >150 ms duration and LBBB, all the guidelines reviewed provide the strongest 
recommendation and evidence levels for implantation.  (Table 3) 
 
Table 3- Comparison of Recommendations for Patients with Sinus Rhythm and LBBB   
 
 
However, discrepancies exist and many of these relate to QRS duration and morphology.  
Recommendations for CRT implantation in patients with sinus rhythm and a QRS duration 
between 120 ms and 129 ms vary greatly between the different cardiology societies.  This is 
particularly visible with the two ESC associations, with ESC EHRA providing a class I 
24 
recommendation (is recommended) for this indication and the ESC HFA providing a class III 
recommendation (is not recommended) (Table 3).  
Another inconsistency in these international guidelines relates to class of recommendations 
awarded patients with sinus rhythm and non-LBBB (table 4). In this patient group large 
variations in recommendation classes between the different guidelines exist. For example, for a 
patient in NYHA functional class III with a QRS duration >150 ms in sinus rhythm with non-
LBBB, the Australian guidelines provide an A recommendation (their strongest) while the other 
guidelines analysed provide either a class IIa or IIb.  
Table 4- Comparison of Recommendations for Patients with Sinus Rhythm and Non-LBBB 
Variations were also noted in recommendations for patients with reduced LVEF and high degree 
AV block who are likely to be dependent on RV pacing (table 5).   This indication was awarded a 
25 
class IIa (should be considered) recommendation by both the 2013 ESC EHRA guidelines and 
the 2013 American guidelines. The 2016 ESC HFA guidelines provided a recommendation class 
I (is recommended).  One year later the Canadian guidelines provided a class IIb recommendation 
(may be considered) for the same indication.  
Table 5- Less Conventional Indication for CRT 
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3.2 Paper 2 -CRT Survey II: a European Society of Cardiology Survey of Cardiac 
Resynchronization Therapy in 11 088 Patients -Who is Doing What to Whom and How? 
 





























In the 42 countries surveyed 97% of patients had symptomatic heart failure (NYHA functional 
class II, III or IV), 69% had sinus rhythm, 73% had LBBB morphology on their ECG, 87% had a 




























On the other hand, 3% of patients had asymptomatic heart failure and 8% had a QRS duration 
<120 ms. 32% of patients were aged ≥ 75 years, 28% were upgraded from a previous device and 
24% of patients implanted with a CRT device were female.  
 
The survey also demonstrated inter-country variations in patients’ selection parameters. Figure 2 
shows NYHA functional class, bundle branch morphology, QRS duration, upgrades from a 
previous device and choice of device type for the countries with the top 10 highest survey 
recruitment.   
Figure 2 CRT Survey II Patients in the Top 10 Recruiting Countries  
 






Figure 2b- Bundle Branch Morphology  
 






Figure 2d-Upgrades from a Previous Device  
 
Figure 2e-Choice of Device Type (CRT-P vs. CRT-D)  
 
The figures presents a comparison of selected characteristics across the top 10 recruiting countries. Asterisks demonstrate 
the level of statistical signif icance of the bottom red category for each country as compared to the total cohort. One asterisk 





3.3 Paper 3 – Cardiac Resynchronization Therapy Pacemaker or Cardiac Resynchronization 
Therapy Defibrillator: What Determines the Choice – findings from the ESC CRT Survey II? 
 
This paper describes the choice of device type (CRT- P vs. CRT –D). This is an area where there 
is limited advice provide by guidelines because of sparse evidence. Of the 11 088 patients 
included in the survey, 10 692 had sufficient data collected to be included in the CRT-P vs.  
CRT-D analysis, and of these 3225 (30%) received a CRT-P device and 7467 (70%) a CRT-D 
device.  Compared with those implanted with a CRT-D device, patients implanted with a CRT-P 
device were significantly older (mean age 75 vs. 68 years, p <0.001), more often female (31% vs. 
21%, p <0.001) and were less likely to have ischaemic aetiology (33 % vs 49%, p <0.001). They 
also had significantly more cardiovascular and non-cardiovascular comorbidities, including atrial 
fibrillation (50% vs. 37%, p <0.001), valvular heart disease (30 % vs. 26%, p <0.001), 
hypertension (67% vs 62%, p <0.001), anaemia (18% vs. 14%, p <0.001), and chronic kidney 
disease (35% vs. 29%, p <0.001). Patients in the CRT-P group were more likely to be receiving 
an upgrade from a previous device either a permanent pacemaker or ICD (26% vs 21%, p 
















A regression analysis to identify factors associated with implanting a CRT-P vs. a CRT-D 
showed that CRT-P was more commonly selected for patients with more severe symptoms of 
heart failure, more frequent comorbidities, advanced age, female gender, non-ischaemic heart 
failure aetiology, atrial fibrillation and evidence of AV block.  Being implanted in a university 








Furthermore, we demonstrated large inter-country variations in choice of CRT-P vs. CRT-D, 
ranging from 88% CRT-P (Bulgaria) to 2% (Turkey). Performing a linear regression analysis we 
were not able to link the percentage of CRT-P implanted in a country with their gross domestic 
36 
production (GDP). We therefore concluded that other national factors must be influencing the 
choice between CRT-P and CRT-D.  
Figure 3 Percentage CRT-P per Country for Countries with >200 patients in CRT Survey 
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3.4 Paper 4 Adherence to ESC Cardiac Resynchronization Therapy Guidelines – Findings from 
the ESC CRT Survey II 
In this paper we analysed adherence to ESC guidelines. 8021 patients with sufficient data were 
analysed for adherence to the ESC EHRA guidelines on CRT. Of these, 67% had a class I 
indication for CRT, 26% a class IIa and 5% a class IIb. Only 2% had a class III indication 
(contra-indicated).  (Table 10) 
 
 
Table 10 – Adherence to ESC EHRA 2013 CRT Guidelines  
 
Recommendation Class N Percent of total  
I 5358 67% 
IIa 2126 26% 
IIb 408 5% 
III 129 2% 
 
 
Details of patient characteristics for patients in the two largest groups (class I and IIa) are 






Table 11– Patient Characteristics for CRT Indication Class (I vs. IIa) According to ESC EHRA 
2013 Guidelines 27.  
 
  Recommendation Class   
  I (n= 5358) IIa (n= 2126) p-value  
Median age (year, IQR) 68 (61, 75) 72 (65, 78) <.00001 
Female (%) 28.5 % (1525/5354) 18.2 % (386/2126) <.00001 
Elective admission 82.6 % (4422/5355) 70.0 % (1487/2124) <.00001 
Ischaemic HF aetiology 43.0 % (2298/5349) 48.4 % (1029/2125) 0.01324 
        
Past history and major comorbidity       
Myocardial infarction 35.3 % (1886/5350) 39.7 % (843/2124) 0.00033 
Prior revascularization (PCI/CABG) 37.6 % (2014/5351) 41.7 % (883/2120) 0.00133 
Hypertension 61.9 % (3306/5343) 66.5 % (1407/2116) 0.00019 
Valvular heart disease 22.8 % (1218/5352) 35.5 % (755/2126) <.00001 
Obstructive lung disease 11.7 % (625/5353) 13.2 % (280/2124) 0.07160 
Diabetes 31.1 % (1663/5351) 34.5 % (733/2125) 0.00431 
Anaemia 13.0 % (697/5351) 18.8 % (400/2126) <.00001 
Chronic kidney disease (eGFR <60) 27.5 % (1466/5340) 40.8 % (867/2124) <.00001 
Dialysis 3.4 % (50/1460) 2.4 % (21/865) 0.17690 
HF hospitalization during past year 48.5 % (2596/5354) 53.3 % (1133/2125) 0.00016 
        
Pre-procedure ECG       
QRS duration (ms, median, IQR) 160 (150, 180) 160 (140, 174) <.00001 
Sinus Rhythm  93.3 % (4994/5355) 31.1 % (661/2123) <.00001 
Atrial fibrillation  4.5 % (239/5355) 66.1 % (1404/2123) <.00001 
        
Successful  implantation 97.5 % (5285/5421) 97.1 % (2079/2141) 0.34227 
Type of device       
CRT-P 19.6 % (1036/5282) 38.7 % (804/2076) <.00001 
CRT-D 80.4 % (4246/5282) 61.3 % (1272/2076) <.00001 
  
       
 
The majority of patients implanted with a class I indication for CRT were male (72%) and were a 
median of 4 years younger, had less comorbidity (including valvular heart disease, anaemia and 
renal failure)  and fewer previous hospitalizations than those with a class IIa indication. They 
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were also more likely to receive a CRT-D (80%).  For patients implanted with a class IIa 
indication, more were male (82%), more had ischaemic heart disease and additional 
cardiovascular comorbidities (atrial fibrillation, hypertension and valvular heart disease) and non-
cardiovascular comorbidities (chronic kidney disease, diabetes and anaemia).  
The results of the guideline analyses per country are shown in Figure 4. The percentage of 
patients implanted with a class I indication in countries with >200 patients recruited in the Survey 
varied from 44% (Sweden) to 76% (Turkey).   
Figure 4 - Patients Implanted with Class I and IIa CRT Indications (for Countries with >200 

















Of the 11 088 patients included in the analysis, 7920 of 8021 had sufficient data entered to be 
included in the regression analysis. Multivariate analysis showed that women, patients <75 years, 
patients with non-ischaemic aetiology and those admitted electively were more likely to receive a 
CRT device with a class I indication. There were no significant differences in the proportions of 
patients with class I vs. class II CRT indications between high- and low-volume CRT implanting 
hospitals or between those associated with a university and those not associated with a university.  
The results are shown in table 12. Males, patients ≥75 years and patients admitted acutely are 
therefore more likely to be offered a CRT where the evidence level is lower.  
 
Table 12 – Multivariate Regression Analysis - Characteristics Associated with Being Implanted 
Under Recommendation Class I  
Characteristics   Estimate  P-value Odds Ratios (95% 
CI) 
Male gender  -0.5274 <.0001 0.59 (0.52-0.67) 
Age  ≥ 75 years -0.4394 <.0001 0.64(0.58-0.71) 
Elective admission 0.6280 <.0001 1.87 (1.68-0.90)  
Ischaemic aetiology  -0.1983 <.0001 0.82 (0.74-0.90) 
Implanted in 
University hospital  
-0.0231 0.7330  
Implanted in High 
Volume Centre (≥100 
per year)  










About halfway through the CRT Survey II recruitment period another ESC society -the Heart 
Failure Association- released updated guidelines on heart failure treatment that included a section 
on CRT. 8 (Table 13). These included an increase in the lower limit of QRS duration from 120 ms 
to 130 ms and the lowering of the recommendation from class I to IIb for patients requiring an 
upgrade to a CRT from a pacemaker or ICD. The third major change was for patients with left 
ventricular dysfunction, a conventional indication for a pacemaker and expected high percentage 
of right ventricular pacing where the CRT recommendation was increased from class IIa to class 
I.   
After the release of the ESC HFA guidelines there was a significant increase from 21% to 27%  
(p <0.001) in the number of patients implanted with class I indication for avoidance of RV 
pacing. 8  In contrast, the percentage of patients upgraded to CRT due to worsening of heart 
failure remained unchanged at 5%.  Following the lower limit for QRS duration for CRT 
implantation being raised to 130 ms there was a small but statistically significant increase in the 
number of patients implanted with a QRS duration between 120 -129 ms (7% before 2016 versus 
10% after May 2016, p<0.001).  
 
Table 13 European CRT Guidelines  
European CRT Guidelines    
Year  2013 2016 
Society  EHRA HFA 
Minimum recommended for CRT implantation 120 ms 130 ms 
Upgrade to CRT from PM or ICD, recommendation class I  IIb  






Randomised controlled trials provide the evidence that is reviewed by guideline task forces and 
incorporated into recommendations. Registries and surveys describe clinical practice, provide an 
opportunity to assess the implementation of guidelines and identify areas of practice requiring 
further research. 24 Good adherence to guideline-recommended HF medication therapy is 
associated with improved prognosis and several studies have analysed adherence to optimal 
medical therapy and the effect on clinical outcomes.25  However, there is limited research on 
adherence to device therapy guidelines.  
 
In this PhD thesis current international recommendations for CRT are compared and contrasted.  
Areas of inconsistency are identified and the evidence for CRT is reviewed in an attempt to 
explain why these variations are present.  
 
Furthermore, using the population of CRT Survey II we have demonstrated variations in practice 
and guideline adherence in 42 ESC member states and attempted to explain why these exist based 
on guideline recommendation and the evidence behind these recommendations. The choice of 
device type between CRT-D and CRT-P was specifically selected as an area where no firm 
guidance is provided by the international cardiology societies and therefore hypothesized to be an 







4.1 Paper 1 – Indications for Cardiac Resynchronization Therapy: A Comparison of the Major 
International Guidelines. 
 
In the international guideline comparison we demonstrated mainly consistency in the CRT 
recommendations. Such concordance in the guidelines was especially obvious for indications 
where the evidence is very strong, such as in patients in sinus rhythm, with LBBB, symptomat ic 
heart failure and with QRS duration >150 ms. However, for several patient populations there 
exist inconstancies for how strongly CRT therapy is recommended. Many of these relate to QRS 
duration and morphology. One of the most striking is the difference between recommendation 
classes between the two ESC societies for patients with sinus rhythm, LBBB and a QRS duration 
between 120 ms and 129 ms. The ESC ERHA guidelines provide a  recommendation class I (is 
recommended) and  ESC HFA provide a class III  recommendation (is not recommended). This 
inconsistency is likely due to the timing of release of these two guidelines. The ESC EHRA 
guidelines were published in 2013 and the ESC HFA guidelines were published in 2016. Between 
the publication of these two ESC guidelines the results of the Echo CRT trial were released 
showing no reduction in hospitalization or mortality rates for CRT in otherwise eligible patients 
with a QRS durations <130 ms. 18  
 
Another area where there are large inconsistencies in the international guidelines relates to class 
of recommendations awarded patients with sinus rhythm and non-LBBB ECG morphology. For 
patients in NYHA functional class II heart failure with non-LBBB, the recommendation classes 
vary from a strong recommendation A (Australian guidelines, their strongest recommendation) to 
IIa or IIb (all other guidelines reviewed). This, again, is assumed to be related to timing, as the 
oldest guidelines from Australia were published in 2011 and do not distinguish between LBBB 
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and non-LBBB when providing their recommendations.  The evidence that led to a stronger 
recommendation class provided for LBBB came from subgroup analysis of the MADIT-CRT and 
the REVERSE trial, which showed greater benefit of CRT in LBBB. 15, 16 Therefore guidelines 
written after these publications differentiate LBBB from non-LBBB and provide a higher 
recommendation class for LBBB. However, these are subgroup analysis of RCTs with the 
majority of patients having LBBB. 15 16 So the evidence leading to this international weakening 
of the recommendation for CRT for patients with non-LBBB is not as strong as that which led to 
the QRS duration upper limit being raised to 130 ms.  
 
However not all discrepancies were related to timing of evidence publication and guideline 
production. For patients with reduced LVEF and high degree AV block who are likely to be 
dependent on RV pacing the variations in guideline recommendations are more complex than 
simply due to timing. This indication was awarded a class IIa (should be considered) 
recommendation by both the 2013 ESC EHRA guidelines and the 2013 American guidelines. In 
2013 the Block-HF trial was published and showed that biventricular pacing was superior to right 
ventricular pacing in patients with reduced LVEF, HF and AV block. 19 The 2016 ESC HFA 
guidelines raised the recommendation class to class I (is recommended). However, one year later 
the Canadian guidelines provided a class IIb recommendation (may be considered), evidence 
moderate for the same indication. Thus guideline task forces are providing varying degrees of 






4.2 Paper 2 - CRT Survey II: a European Society of Cardiology Survey of Cardiac 
Resynchronization Therapy in 11 088 Patients-Who is Doing What to Whom and How? 
 
In the CRT Survey II we demonstrated that the majority of patients selected for CRT 
implantations in Europe had the clinical characteristics shown to be amenable to CRT and 
therefore recommended by the guidelines, such as sinus rhythm, wide QRS, LBBB, low ejection 
fraction and symptomatic heart failure. However, the survey also demonstrated that some CRTs 
were being implanted ‘off label’, that is, outside guideline recommendations such as in patients 
with asymptomatic heart failure (NYHA functional class I) and QRS duration <120 ms. None of 
the international guidelines recommend CRT in patients without symptomatic heart failure, 
however in CRT Survey II 3 % were classified in the NYHA I functional class.  Regarding 
narrow QRS duration, our survey shows that 8% of implants were in patients with a QRS      
<120 ms. Again, none of the international guidelines recommend CRT implantation in patients 
with a CRT duration <120 ms.  However, the median QRS duration was narrower (144 ms 
compared with 160 ms) for patients implanted only for the clinical indication ‘pacemaker 
indicated and expected right ventricular pacing dependence’ compared to the overall cohort. This 
indication does not specify the requirement for a wide complex, so this could partially explain 
why 8% of patients in our survey were implanted with a CRT despite having a QRS duration 
<120 ms. A total of 10% of the survey population was implanted with only this clinical indication 
and 22% of this group had a QRS duration <120 ms.  
 
Furthermore, although by no means outside guideline recommendations, there was a large 
number of CRT implantations being undertaken in patient groups where there was a limited 
evidence base such as patients age >75 years,  upgrades from a previous device (pacemaker or 
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ICD), patients with non-LBBB and patients with atrial fibrillation. These implantations suggest 
that clinicians continue to extrapolate data from RCT to patients who are not well represented in 
the evidence base. Clinical practice may be guided by clinical trials but differences in practice 
exist because clinicians have accumulated experience and try to offer the best treatment to 
individual patients, many of whom do not fulfil the selection criteria for the RCTs. Compared to 
patients enrolled in RCTs, patients in this survey were generally older, had more co-morbidities, 
were less likely to have ischaemic heart disease, had higher LVEF, narrower QRS complexes and 
more atrial fibrillation but a similar proportion were women. 28 
 
In the survey we also showed large inter-country variations in patient selection parameters. 
Country variations were particularly evident in areas where there was limited evidence base e.g. 
patients > 75 years, upgrades from a previous device (pacemaker or ICD) and choice of device 














4.3 Paper 3 – Cardiac Resynchronization Therapy Pacemaker or Cardiac Resynchronization 






    
  
  
   
    
    
 
International  guidelines  do not provide  firm  recommendations  regarding choice  of  device  type
(CRT-P vs. CRT-D). Most patients  with  an  indication  for a CRT  device  also  have  an overlapping
indication  for  ICD implantation  due to the risk  of  ventricular  arrhythmias  associated  with  the
reduced  ejection fraction. 8, 29 However  no study  has been designed  or powered to directly
compare  CRT-P vs.  CRT-D for clinical  outcomes, limiting  the ability  of guidelines  to advise  on
choice  of device  .11 The  ESC EHRA  guidelines do list  some  factors  in  their guidelines  that  should
be considered  to weigh  in favour of implanting  a CRT-P versus  a CRT-D; these  include
advanced  heart  failure,  severe  renal  insufficiency  or dialysis,  and other  major  co-morbidities
including  frailty  and cachexia.  CRT-D is suggested  for patients  with  a life  expectancy >1 year, in
NYHA functional  class  II, ischaemic  heart  disease,  and no major  co-morbidities. 27 The  ESC
HFA guidelines  state that  if  the  primary  reason  for  implanting  a CRT is  to improve  prognosis,
most  evidence  lies  with  CRT-D in  patients  with NYHA  functional  class  II and for  CRT-P for
patients  in  NYHA functional  classes  III to IV.  However,  if  the primary  reason  for implanting  the
device  is relief  from  symptoms,  HFA guidelines  propose that  the clinician  should  choose between
a CRT-P and  a CRT-D, as he/she  considers  appropriate. 8 The  NICE guidelines,  specific  to the
UK, provide  clear  recommendations  on type of  device  depending  on NYHA  Class and QRS
duration  and morphology  but remain  silent  on the  effects  of co-morbidities  and age  on the
relative  benefit  of  CRT-D over CRT-P. 30 However, neither  of  these suggestions  are accompanied
by strength of recommendation or evidence  level.
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In CRT Survey II we showed that 70% of CRT recipients in Europe received a device with 
defibrillation capacity. The CRT-P recipients were significantly older, were more symptomatic of 
their heart failure, were more often female and more often had additional conduction tissue 
disease. They also had significantly more comorbidities including atrial fibrillation, valvular heart 
disease, hypertension, anaemia, and chronic kidney disease. Overall it appears possible that in 
patients selected for CRT-P, operators are appreciating the limited clinical effectiveness of ICD 
therapy in older and frailer patients.  This is consistent with the limited guidance provided in the 
most recent EHRA ESC guidelines. On the other hand, patients implanted with a CRT-D device 
were more likely to have ischaemic heart failure aetiology, probably reflecting the stronger 
guideline levels of evidence for an ICD in patients with ischaemic aetiology than in those with 
non-ischaemic aetiology. 8 
 
The percentage of CRT-P vs. CRT-D varies greatly in different regions and countries. 31In CRT 
Survey II the percentage of CRT-P devices ranged from as low as 2% to as high as 88 % (figure 
3).32   This variation could not be explained by economic factors alone, other factors like 
reimbursement policies may come into play as countries with comparable financial resources 
show markedly different implantation behaviour.  
 
The limited advice provided by guideline task forces related to choice of device is likely due to 
the lack of studies comparing these two devices. Only one head-to-head study of CRT-D vs. 
CRT-P has ever been published. However, this study (COMPANION) was not designed to 
compare different CRT devices; rather, it focused on the overall concept of CRT versus optimal 
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medical therapy. It established the benefit of a CRT over medical therapy in eligible patients, but 
was underpowered to compare any difference between CRT-P and CRT-D.7  
 
The majority of comparisons of CRT-P vs. CRT-D have been retrospective cohort studies and 
these have suggested that the benefit for a CRT-D over a CRT-P may be limited to those patients 
with ischaemic heart failure aetiology. 20, 33, 34 
 
The only recent RCT of defibrillator over standard care, the DANISH study, randomized 556 
patients with heart failure of non-ischaemic aetiology with an LVEF ≤35% to either receive an 
ICD or usual clinical care. Despite the rate of sudden cardiac death being half in the ICD group 
(4.3%) compared with the control group (8.2%) this trial showed no significant difference in 
overall survival benefit between the two groups. There was, however, an age interaction 
suggesting that the benefits of ICD in patients with non-ischaemic aetiology were limited to the 
younger patients (<68 years of age). 35 In both the ICD and the control group 58% of the patients 
received a CRT device and these results were independent of whether or not the patients received 
a CRT.  Therefore, this study enabled the direct comparison of 323 CRT-P patients versus 322 
CRT-D patients with ischaemic heart failure aetiology. The DANISH study suggests that in 
patients  ≥68 years of age with heart failure due to non-ischaemic aetiology the increased 
mortality rate is not due to sudden cardiac death but rather to another mode of death for which an 
ICD does not improve mortality rates.  
 
In the French CeRtiTuDe registry, 1705 recipients of either a CRT-P or a CRT-D were followed 
rigorously for adjudicated causes of death over 2 years. 36 The CRT-P patients were older (mean 
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age 76 years), less often male, had more symptoms of heart failure, less often had heart failure of 
ischaemic aetiology and more patients had atrial fibrillation and other co-morbidities.  Although 
in CeRtiTuDe mortality was double in the CRT-P vs the CRT-D group, this increased mortality 
rate was due to non-sudden cardiac death in the CRT-P group, thereby suggesting that the 
patients who are routinely selected for a CRT-P would not benefit from a CRT-D.  
In short, CRT reduces but probably does not completely abolish the risk of sudden cardiac death. 
The likely mechanism is related to reverse remodelling following successful resynchronization. 37 
Therefore, it has been speculated that a CRT-P may provide adequate protection from the 
increased mortality that these patients face and that they may not require the defibrillator part of 
the device. 
Whether the patients actually required the defibrillator is important to consider, since the addition 
of the defibrillator component is not without potential adverse procedural complications 
including the risk of inappropriate shocks. 38, 39 
 
Perhaps providing implanters with a scoring system for patient selection would assist in 
appropriate patient selection.  Several risk scores such as the Goldenberg risk score have been 
proposed to identify patients with a limited survival benefit from a CRT-D, who may therefore be 
implanted with a CRT-P rather than a CRT-D.  40 41 Such risk scores may prove useful in 




However, in order to properly resolve the P vs. D question, we would require a large, randomized 
controlled trial directly comparing the two types of CRT devices. Fortunately, the RESET-CRT 
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trial is underway in Germany (ClinicalTrials.gov number NCT03494933). In this study 2030 
patients with both ischaemic and non-ischaemic HF aetiology will be randomized to a CRT-P or 
CRT-D. The primary endpoint of this study is all-cause mortality. Hopefully, the results of such a 
trial will shed more light on this important and clinically relevant issue, thereby allowing 
guidelines to provide a clearer recommendation in which patients to implant a CRT-P and in 
which to implant a CRT-D.  
 
4.4 Paper 4 -Adherence to ESC Cardiac Resynchronization Therapy Guidelines – Findings from 
the ESC CRT Survey II  
In this paper we examined adherence to guidelines and demonstrated that there is good adherence 
to the ESC EHRA CRT guidelines in the ESC countries surveyed. In CRT Survey II 67% of 
patients were implanted under recommendation class I and only 2% under recommendation class 
III.  
 
We grouped the patients included in the survey according to which CRT indication they were 
implanted under and demonstrated that patients were more likely to be considered for a CRT 
under a weaker indication if they were male, age ≥ 75, had heart failure of ischaemic aetiology 
and were admitted to hospital acutely.  
 
Patients admitted to hospital electively for CRT implantation were more likely to have class I 
indications than those admitted as an emergency, possibly due to a more systematic outpatient 
review. In contrast, non-elective admissions tended to be associated with prolonged hospital stays 
and these patients were more likely to receive a CRT device with a weaker indication. This may 
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be affected by a collaborative approach to therapeutic options in a hospital setting with more than 
one physician involved in the decision-making process.  
 
We demonstrated large inter-country variations in the percentage of patients implanted under 
recommendation class I.  These were mirrored by large variations in number of patients 
implanted under recommendation class IIa (should be considered). We postulated that a low 
percentage of patients implanted under recommendation class I does not necessary imply poor 
guideline adherence, but rather a willingness and ability to expand to implanting based on a wider 
indication and less evidence such as rapidly adopting new indications from trials like BLOCK 
HF. 19 These differences may reflect academic research interests or national culture. Certain 
countries are also highly dependent on strict recommendation class I guideline adherence in order 
to get reimbursement for the devices implanted, which likely accounts for some of the inter-
country variation seen in our survey.  
 
In this paper we also reported the results of an exploratory analysis of our data regarding the 
release of the ESC HFA 2016 guidelines. 8 We wished to identify whether the release of these 
guidelines half-way through the survey recruitment period affected clinical practice. The stronger 
recommendation for patients expected to be dependent on RV pacing was associated with a 
significant increase in the proportion of patients implanted with this indication. In contrast, the 
downgraded recommendation for upgrading to CRT due to worsening of heart failure did not 
have an impact, suggesting that physicians continued to believe that this indication is appropriate 
in clinical practice. The same was true of the stricter QRS duration criterion (>130ms), which did 
not appear to change practice as there was an increase in percentage of patients implanted with a 
QRS duration between 120 ms and 130 ms after the HFA guideline release.  However, few 
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patients were implanted with a QRS of 120-130 ms.  This could indicate that the higher QRS cut-
off had already been implemented in many centres following the publication of the ECHO CRT 
trial in 2013 which clearly indicated increased mortality in patients with QRS duration     
≤130ms. 18 Furthermore, although both the EHRA 2013 and HFA 2016 guidelines are endorsed 
by the ESC, they are written by two different associations representing electrophysiologists and 
heart failure physicians respectively. It could be expected that electrophysiologists were less 
likely to adhere to changes in guidelines produced by the HFA than if the guideline change had 
been produced by EHRA.   
 
Several previous publications from registries have demonstrated under-utilization of CRT.42-44 
However, none of these studies assessed the adherence to ESC Guideline recommendations for 
CRT in patients implanted with a CRT device. A small retrospective study from the Netherlands 
in 2012 showed that 92% (45/49) of patients with a class I indication for a CRT underwent 
implantation (using the 2010 ESC focused update of ESC Guideline for Device Therapy in Heart 
Failure). 45 A larger study of 930 patients implanted with a CRT device reported that 61% had a 
class I indication and that these patients had lower mortality, fewer HF hospitalizations and more 
evidence of remodelling than those with other indications. 46 A recent survey of implanting 
centres’ attitudes to guideline adherence indicated that in patients with class I indications and a 
QRS duration >150ms, 100% would implant a CRT device. However, with a QRS duration 
between 120 and 150ms, only 89% would recommend CRT.47 67% of centres said they would 
implant CRT devices for class IIa indications and only 17% for IIb indications. Interestingly, 2% 
of centres said they would implant CRT devices in patients with class III indications due to a 
QRS duration <120 ms, the same proportion as in this survey.  
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4.5 National Publications from CRT Survey II 
Of the countries participating in CRT Survey II eleven have published national publications 
benchmarking their countries data against the total cohort. 48-58 Overall, patient selection and 
guideline adherence was similar in the 42 participating countries. However, these publications 
have highlighted some interesting differences.  Georgia implanted few patients ≥ 75 years of age 
compared with the total cohort (13% vs. 32%, p<0.001) while France on the other hand had a 
much larger proportion of patients implanted ≥ 75 years (45%). 48, 49 Belgium implanted a 
significantly higher percentage of women with a CRT than the total cohort (33% vs. 24%, 
p<0.001 ) 50  In Spain there fewer percentage of patients with heart failure of ischaemic aetiology 
compared with the total cohort (38 % vs 45%, p<0.001). 51 A possible explanation offered for this 
finding was that Spain has a rather low national implantation rate and perhaps implanter are 
reserving CRT for patients for whom they believe the best benefit could be obtained. Croatia, 
Bulgaria, Poland, Switzerland and Germany all reported higher co-morbidities in their CRT 
population compared with the total cohort.52, 54-57  Possible explanations for the higher rate of co-
morbidities in patients in Germany is speculated to be a reluctance in other European countries to 
implant CRT in ‘sicker’ patients.   In Bulgaria patients also appear to be referred later for a CRT 
device as more patients were in NYHA Class III or IV.57  The Croatian population had a large 
number of patients implanted with LBBB (80%) and wide QRS complex (68% >150ms). Such 
large emphasis on QRS morphology and duration is believed to be due to health care budget 
restrictions in Croatia.  52 Bulgaria, Croatia and Switzerland had lower percentage CRT-D than 
the total cohort. 52, 55, 57 The Croatian and Bulgarian implanters attribute this lower percentage to 
budgetary restriction; in Bulgaria CRT-D is not fully reimbursed and patients are not always able 
to afford co-payments for these devices. Switzerland, on the other hand, has a reimbursement 
system that allows for easy access to available technology. They have attributed the higher rates 
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of CRT-P to the fact that their patients were older and that more often the CRT device was 
implanted by an electrophysiologist, who potentially would be more aware of the latest evidence 
suggesting that a CRT-P through reverse remodelling might reduce the need for a CRT-D. 
Therefore, despite not have the economic restraints of Croatia and Bulgaria, electrophysiologists 
in Switzerland preferentially select the less expensive CRT-P device with the primary goal of 
relief of heart failure symptoms.  The Czech Republic reported a high percentage of patients 
implanted with a QRS duration <120 ms (13% vs. 7%, p<0.001) and linked this to their high 
percentage of patients with atrial fibrillation (47% had a past medical history of atrial fibrillation 
vs. 40%, p<0.001) and assume that these were likely to be implanted with a CRT prior to AV 
junction ablation. 53   
 
Scandinavia (Norway, Sweden and Denmark) reported a higher percentage of patients who had 
AV block or were pacing dependent (49% vs. 33%, p<0.001) with more patients implanted due to 
pacemaker indication and expected RV pacing dependence (36% vs. 22%, p<0.001). 58 The 
explanation offered for this higher rate in Scandinavia is that they are adopting the practice of 
implanting a CRT rather than a traditional pacemaker in patients with reduced LVEF and a high 
degree of AV block to avoid worsening of LVEF due to a high rate of RV pacing. This was 
demonstrated by the BLOCK HF trial and the HFA guidelines raised the recommendation class 
for this indication from a class IIa in the EHRA guidelines to a recommendation class I with 
evidence level A. 8, 19, 27  
 
Although there was mainly consistency in practice in Europe, several interesting differences are 
reported and many of these are attributed to economical differences between countries. Several of 
these national publications also highlight the difference between their countries’ percentage of 
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CRT-P vs. CRT-D with that of the total cohort. These differences are often attributed to national 
spending patterns but may also be related to the imprecise recommendations provided by the 
guidelines.  
 
4.6 Comparison of CRT Survey I vs. CRT Survey II  
The inspiration for conducting CRT Survey II came from the success and findings of the first 
ESC CRT Survey (CRT Survey I) conducted in 2009. 59-63  CRT Survey I analysed data on 2438 
patients implanted with a CRT device in 13 ESC member countries. At the start of the ESC CRT 
Survey, the most current guideline recommendations for a CRT were the 2008 HFA guidelines, 
which recommended implantation in patients with EF ≤ 35%  in NYHA Class III and IV heart 
failure with a QRS duration >120 ms.  64  CRT Survey I found that that implanters were 
implanting a substantial number of devices outside the guideline recommendations, including 9% 
with QRS duration <120 ms, 20% in NYHA Class II , 2% in NYHA Class I and 23% of patients 
with AF.  60 Furthermore, 26% of patients implanted had a previous device and 31% were ≥75 
years old.  Although not outside guideline recommendations, both are patient groups for which 
there was and still is little RCT evidence of CRT effect.  
All 13 countries participating in CRT Survey I also participated in CRT Survey II.  These 
countries included Austria, Belgium, France, Germany, Ireland, Israel, Italy, Netherlands, 
Norway, Spain, Sweden, Switzerland and the United Kingdom.  CRT Survey II collected data 
from 5313 patients in these 13 countries. In the years between the two surveys several large 
RCTs were performed with patients with milder heart failure (NYHA II): REVERSE, MADIT-
CRT and RAFT 4-6. These trials all concluded that the addition of a CRT device was associated 
with reduced rates for heart failure events in patients with NYHA Class II heart failure. RAFT 
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was also able to demonstrate a mortality benefit. This led to more recent ESC guidelines to 
include patients in NYHA class II in their CRT recommendations. 8, 17, 27  Our comparative 
analysis of CRT Survey I and II showed that clinical practice has evolved along with the 
guidelines with CRT Survey II including 40% patients in NYHA Class II compared with 20% in 
CRT Survey I.  
 
Subgroups analysis of both the REVERSE and MADIT-CRT trials showed better response in 
patients with LBBB morphology than in those without, leading guidelines to divide their 
recommendations according to bundle branch morphology with a stronger recommendation 
awarded patients with LBBB.  8, 15-17, 27  Our comparative analysis of CRT Survey I and II has 
again shown that clinical practice has evolved in line with guideline recommendations;  in CRT 
Survey II 73% patients had LBBB compared with 68% in CRT Survey I.  
 
The most current guidelines at the start of CRT Survey I (2008 HFA guidelines) did not specify 
that the underlying rhythm be sinus for a recommendation class I for CRT and there was no 
mention of CRT in patients with atrial fibrillation. 64 Observational data and subgroup analyses 
showed conflicting results regarding the effectiveness of CRT in patients with atrial      
fibrillation. 65-67 The lack of firm evidence of effect of CRT in patient with AF has led the most 
recent ESC guidelines to provide patients with a lower recommendation class that those in sinus 
rhythm. 8, 27 These less strong recommendations for patient with AF are reflected in clinical 




CRT Survey II in line with CRT Survey I has further demonstrated that CRT is being implanted 
in patients for whom there is limited evidence from RCT, such as those ≥75 years of age (39% in 
II and 31% in I) and those upgraded from a previous device (25% in II and 26% in I).   
 
CRT Survey I also found that high volume centres were more likely to explore newer indications 
in their CRT practice by implanting more patients with mild symptoms and narrow QRS  
duration 61  In CRT Survey II this was the case for narrow QRS duration (high volume centres 
10% <120 ms vs 6% >120 ms for low volume centres). This finding could be partially explained 
by the large percentage of patients implanted with a pacemaker indication and expected RV 
pacing dependence (high volume centre 24% vs. 22% low volume). However, in CRT Survey II 
there was no difference in patients implanted in NYHA Class I or II for high versus low volume 













4.7 CRT in important subgroups  
 
4.7.1 CRT in Women  
International CRT guidelines do not categorize CRT recommendations based on gender. 
However, the ESC EHRA 2013 guidelines did suggest that women respond better to CRT therapy 
than men.27  
 
In our primary publication of CRT Survey II we reported that only 24% of patients implanted 
with a CRT in Europe are women. 68 The women implanted in CRT Survey II had significantly 
less ischaemic heart failure aetiology (25%) than men (51%) with 20% of women having had a 
previous myocardial infarction compared with 42% of men. Despite achieving statistical 
significance, their median QRS durations (160 ms for both, p<0.001) and LVEF (30% for 
women, 28% for men, p<0.001) were similar. Therefore we found that apart from a substantial 
difference in percentage of patients with heart failure of ischaemic aetiology, men and women 
implanted with CRT in this survey had similar demographics and clinical characteristics.  
 
In our CRT-P vs. CRT-D analysis (paper 3) we found that women were also less likely to receive 
a CRT-D 32. In our guideline analysis paper (paper 4) we demonstrated that women appear to 
receive CRT implantation predominantly when the indication is very strong while men patients 
are more likely to undergo CRT implantation with less strong indications. This could represent a 
gender bias and may partially explain the low proportion of CRT implants in women.  In another 
publication from CRT Survey II we demonstrated that female patients more often experienced 
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intra- and periprocedural complications such as pneumothorax, pericardial tamponade, coronary 
sinus dissection and lead dislodgment.  69 
 
The low percentage of women implanted with a CRT can partially be explained by the fact that 
women develop heart failure at older age than men.  Women are also more likely to develop HF 
with persevered ejection fraction than heart failure with reduced ejection fraction and thereby not 
quality for a CRT.70 This low percentage of women implanted with a CRT-D found in CRT 
Survey II is consistent with the findings from recent European Registry in which only 19% of 
primary preventive ICD recipients were female. 71  
 
The increased complication rate seen in women in CRT Survey II is consistent with observations 
from the Danish Cardiovascular Implantable Electronic Device Registry and the US National 
Cardiovascular Data Registry (NCDR) report which also found more device-related 
complications in women. 39, 72 The reasons for this increased risk of complications in women is 
unclear but it has been speculated that it is related to differences in body composition, including 
smaller vascular and cardiac dimensions, smaller body weight, and hormonal differences. This 
increased complication risk could be one of the factors limiting the implantation of these devices 
in women.  
 
The underutilization of CRT in women is particularly unfortunate considering that there are 
several studies, including sub-analysis of RCTs, meta-analysis and registry data, suggesting that 
women have a greater benefit from CRT than men. 73-79  The mechanisms postulated to explain 
this increased benefit of CRT in women include greater reverse remodelling in women with 
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greater reduction in LV volumes and improvement in LVEF,  more LBBB in women, LBBB at 
narrower QRS in women, and the fact that women more often have heart failure of non-ischaemic 
aetiology.70, 73, 74, 80-82  In CRT studies patients with non-ischaemic HF aetiology have a better 
overall prognosis than patients with ischaemic aetiology in both the control arm and the CRT 
arm. 83 Post hoc analysis of the MADIT-CRT and COMPANION trials also showed that patients 
with LBBB had greater benefit of CRT than patients with non-LBBB. 15, 16  Finally, body size 
may be a factor which has been overlooked. In an individual patient meta-analysis of five RCTs 
with 3496 patients women were generally shorter than men but about a fourth of men were also 
‘short’. 84 In this meta-analysis with a composite outcome of mortality and HF-related 
hospitalizations, only height and QRS duration, but not sex, were independent predictors of CRT 
benefit.  This meta-analysis generates the hypothesis that height may be a new factor to be 
considered in CRT implantation, in particular in patients with shorter QRS durations, and that 
other yet unidentified factors may predict CRT response. 
 
Unfortunately, it is difficult to assess sex differences in CRT treatment because of the low 
number of women enrolled in HF trials including CRT trials. 85 In the pivotal CRT trials the 
percentage of women ranged from 19% to 33%. 1-7  
 
One of the most recent guidelines released by the ESC on the treatment of ST elevation 
myocardial infarction (STEMI) included in its key messages a section on gender aspects stating 
that ‘Women tend to receive reperfusion therapy and other evidence-based treatments less 
frequently and/or in a delayed way than men. It is important to highlight that women and men 
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receive equal benefit from a reperfusion and other STEMI related therapies, and so both genders 
must be managed equally.’ .86  Unfortunately, the most recent ESC guidelines relating to CRT do 
not include such a statement.  Perhaps this should be included in any future update of the 
guideline so that more eligible women are offered this treatment.  
 
 
4.7.2 CRT in the Elderly  
International guidelines do not suggest an upper age limit for CRT implantation. There is 
however some guidance regarding age and co-morbidities provided by a few of the international 
guidelines regarding the choice of device type. The Canadian guidelines state that CRT-P should 
also be considered in patients who are not candidates for ICD therapy because of limited life 
expectancy and significant co-morbidities.87 ESC EHRA guidelines provide guidance on whether 
to place a CRT-P or a CRT-D depending on the co-morbidities of the patient. 27 The 2012 EHRA 
and Heart Rhythm Society Expert Consensus Statement on CRT in Heart Failure suggests 
performing a comprehensive assessment of comorbidities prior to selection of patients for     
CRT. 88 However, overall there is limited concrete advice in international guidelines regarding 
the impact on clinical decision-making of age and comorbidities in the individual patients. 
 
In CRT Survey II 32% of patients included were ≥ 75 years of age. These patients were more 
frequently in NYHA Class III or IV (66% vs. 56%, p<0.001). The older patients had more 
comorbidity including hypertension (72% vs. 60%, p<0.001), atrial fibrillation (33% vs. 22%, 
p<0.001), anaemia (20% vs. 13%, p<0.001) and renal dysfunction (45% vs. 25%, p<0.001). They 
also had significantly higher median NT-pro BNP levels (3510 pg/ml vs. 1968 pg/ml, p<0.001) 
than younger patients. Despite substantially more patients ≥ 75 years of age having heart failure 
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of ischaemic aetiology (50% vs. 42%, p<0.001) compared with those <75 years of age, far fewer 
patients in the oldest group were implanted with a CRT-defibrillator (CRT-D) compared with 
those in the youngest group (52% vs. 78%, p<0.001).  
 
Despite the fact that patients ≥75 years of age in CRT Survey II had greater comorbidities and 
experienced more symptoms from their heart failure, they suffered similar periprocedural 
complications (6% vs. 5%, p= 0.263) and adverse events (5% vs. 5%, p= 0.029) during the index 
hospitalization. Our findings suggest that CRT may safely be offered to elderly patients and that 
such patients should not be deprived of this treatment.   
 
Although none of the pivotal CRT trials had an upper age limit for inclusion, the exclusion 
criteria of these trials limited the inclusion of elderly patients. The median age for patients 
included in the CRT landmark trials ranged from 62 to 68 years, therefore limited trial evidence 
exists for CRT in patients ≥ 75 years of age.  1-7   Only CARE-HF actually included some patients  
>75 years 89 Furthermore, several of the exclusion criteria for these trials, including the 
comorbidities – atrial fibrillation and inability to provide informed consent (due to significant 
cognitive dysfunction) - make the data difficult to extrapolate to elderly patients who often suffer 
from such co-morbidities. 90  However, both the prevalence of HF and LBBB increase with age. 
91   
 
Whether CRT is more beneficial to different age groups is unclear since the evidence is 
conflicting. 90 In the MADIT CRT group there was a trend towards greater benefit in patients      
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≥ 65 years; the same was seen in the RAFT (2010) 5, 6 The RESERVE trial (2008) showed an 
opposite trend, with greater response in patients <64 years of age. 4 However, none of these 
observations were significant.90 The COMPANION trial found that patients aged ≥ 65 years had 
greater benefit from CRT-D than from CRT-P compared with younger patients but did not 
provide a p-value for this statement. 7, 90 However, previous observational studies on elderly 
patients have been able to demonstrate benefit. An observational study with two-year follow-up 
comparing CRT in patients ≥ 75 years (107 patients) vs. those <75 years (159 patients) found 
similar improvements in quality of life, NYHA class and LVEF. The patients ≥ 75 years had a 
higher mortality rate. However, this was also non-significant. (35% vs 27%, p =0.36). 92 Another 
study with a similar 2 year follow-up compared CRT in patients ≥ 70 years (68 patients) with 
those <70 years (102 patients) and found that the two groups had similar quality of life and 6-
minute walk distance improvements. 93 However, these were small single studies with small 
number of patients. A similar study of 49 patients ≥ 80 years found that although annualized 
mortality rates were significantly higher in  this group (15% compared with 6% for those <70 
years old) time to death or first heart failure admission was similar in these age groups. 94 
Another study examined mortality data of 90 patients >80 years of age and found they had 
similar clinical benefits to younger patients. 95  
 
Regarding periprocedural complications in the elderly, a sub study of MADIT-CRT found no 
difference in 90 day-complication rate for CRT-D implantation in patients ≥ 75 year of age. 96 
Such sub-analysis has not been performed for the other pivotal CRT trials. 90 However, 
observational data has provided some evidence suggesting that periprocedural complications are 




In a retrospective analysis of CRT in 177 patients >75 years of age there was no difference in 
mortality between he CRT-P and CRT-D groups in this elderly population. 98 A similar result was 
seen with a retrospective analysis of patients aged ≥75 years in Canada. Mortality data were 
compared for 128 patients with a CRT-D vs. 42 with a CRT-P and, again, there was no 
significant difference in mortality or cardiac hospitalization between these two groups. 99 
 
With a CRT-D device there is also the issue of end-of life care which is often more relevant in the 
elderly population. A study of 900 hospice providers found that although 97% admitted patients 
with an ICD only 10% of the hospice providers had a deactivation policy. 100 
 
However, if CRT can improve elderly patients’ functional status, they are likely to require less 
intensive outpatient treatment and likely to spend less time in hospital, thereby reducing the cost 
of their HF treatment. 89 But CRT in itself is an expensive therapy for both the implantation and 
the follow-up. So careful considerations must be made in patient selection also in elderly patients 




4.7.3 CRT in Patients with Atrial Fibrillation  
Both the ESC, the Canadian and the American guidelines provide either a class IIa or IIb 
recommendation for CRT in patients with systolic heart failure and AF. 8, 27, 87, 102  European 
guidelines specify that patients must have LVEF ≤ 35% and NYHA Class III or IV HF. Again, 
the ESC associations disagree on QRS duration (≥130 ms for HFA and ≥120 ms for EHRA).  
While the ACC/AHA/HRS and CCS guidelines simply state that eligible patients must be 
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otherwise suitable for a CRT, the Australian and New Zealand guidelines do not discuss patients 
with atrial fibrillation. 103. In the guidelines that provide recommendations for CRT in patients 
with atrial fibrillation there is consensus that ventricular rate must be adequately controlled by 
pharmacologic intervention or atrioventricular nodal ablation in order to ensure a high degree of 
CRT pacing.   
 
In CRT Survey II 41% of patients had a past medical history of atrial fibrillation and 26% had 
documented atrial fibrillation on their ECG at the time of implantation.  Patients with atrial 
fibrillation and without atrial fibrillation at implantation had similar heart failure aetiologies, with 
44% of patients with atrial fibrillation and 45% (p =0.023) of those without atrial fibrillation 
having heart failure of ischaemic aetiology. However, patients with atrial fibrillation were older 
(median age 72 years vs. median age 68 years, p<0.001), had more advanced heart failure (66% 
NYHA functional class III and IV in the AF group vs. 54% in the non-AF group, p<0.001) and 
more co-morbidities than patients without atrial fibrillation. However, periprocedural 
complications (5% in the AF groups vs. 6% in the non-AF group, p=0.135) and adverse events 
(5% for those with AF vs. 4% without AF, p=0.010) were similar in the two groups.  
 
No substantial sized trial has compared CRT to a pharmacological control group for patients with 
atrial fibrillation. Most of the large trials on CRT excluded patients with atrial fibrillation and the 
trials that included patients with atrial fibrillation were small. 104, 105 At least two trials have 
compared CRT to RV pacing after AV node ablation. These suggest that CRT is superior. 106, 107 
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However, whether this reflects a benefit from CRT or simply avoiding the harm of RV pacing is 
unclear. 
 
However, atrial fibrillation is common in the heart failure population with as many as 10-50% of 
patients with moderate or severe heart failure having concomitant atrial fibrillation. 108 A large 
proportion of these heart failure patients with atrial fibrillation also have wide QRS complexes.109 
Patients with atrial fibrillation should also benefit from CRT if a high rate of biventricular pacing 
dependence is maintained by slowing AV conduction either by pharmacological treatment or by 
assuring total dependence AV node ablation. Observational data and subgroup analyses 
demonstrate conflicting results regarding effectiveness of CRT in patients with atrial fibrillation. 
65-67 Clearly, the benefits of CRT in atrial fibrillation patients should be further investigated in a 
well-designed prospective RCT. 
 
4.7.4 CRT in Patients with Non-LBBB  
For patients with non-LBBB there is considerable variation in international guideline 
recommendations. If the patients has a QRS duration >150 ms and is in NYHA class III/ IV then 
both the two ESC guidelines and the American guidelines suggest that a CRT should be 
considered (recommendation class IIa). The Canadian guidelines provide a ‘may be considered’ 
(class IIb) recommendation for the same indication.  
 
However, where the inconsistency between guidelines is greatest is for patients with non-LBBB 
and a QRS <150 ms with recommendations varying from the strongest recommendation class (A 
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from the Australian guidelines to the weakest III from the American guidelines for NYHA 
functional class II).  This large discrepancy mainly relates to the Australian guidelines not 
distinguishing based on type of bundle branch block in their CRT recommendations. The 
Canadian guidelines do not provide a formal recommendation for this patient group; instead, they 
simply state that there is no clear evidence of benefit from CRT for patients with QRS duration 






Although none of the large RCTs evaluating CRT specified LBBB as selection criteria, most of 
the patients included in these trials had LBBB. Subgroup analyses of RCTs have strongly 
suggested that LBBB morphology was associated with substantially better outcome and therefore 
a stronger recommendation class is provided in the guidelines for patients with LBBB. 15, 16 
However, patients with LBBB tend to have a wider QRS and the data is conflicting as to whether 
LBBB is a predictor of CRT success or whether it is just a surrogate marker for a wide          







In CRT Survey  II, 73% of patients had LBBB.  The  patients  with  LBBB  and non-LBBB  were
similar  in  NYHA functional  class  grouping  and LVEF.  However, patients  with  non-LBBB  were
more  often  male (83% vs. 73%, p<0.001), had more often  heart  failure  of ischaemic aetiology
(51% vs. 42%, p<0.001) and narrower median QRS duration  (140 ms  vs. 160 ms,  p<0.001) than
those  with  LBBB.
69 
 
4.7.5 Right Ventricular Pacing Dependence and Upgrades from a Previous Device 
 
Patients with a high degree of AV block implanted with a traditional two lead-pacemaker can 
display pacing dependence with high amounts of RV pacing. RV pacing has been shown to lead 
to adverse LV remodelling and deterioration of systolic function. 112-115 Mechanistically, RV 
pacing resembles LBBB and, therefore, patients with HF and AV block should benefit from CRT 
therapy. In such patients, biventricular pacing rather than RV pacing alone prevents further 
progression of systolic dysfunction and LV dilatation. 19 However, the benefit of prophylactic 
implantation of CRT device remains unclear and guidelines provide varying recommendation for 
this indication. 11  
 
Interestingly, the avoidance of RV pacing by using a CRT-P rather than a pacemaker was already 
mentioned in the 2008 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic 
Heart Failure, under a contraindication to a pacemaker with a recommendation class III, level of 
evidence C. These guidelines state ‘In HF patients with concomitant indication for permanent 
pacing (first implant or upgrading of a conventional pacemaker) and NYHA class II–IV 
symptoms, low LVEF ≤35%, or LV dilatation, CRT with pacemaker function (CRT-P) should be 
considered. In these patients, the use of right ventricular pacing may be deleterious and may 
cause or increase dyssynchrony. 64 In the 2012 ESC HFA heart failure guidelines patients with an 
indication for conventional pacing and no other indications for CRT were provided with a 
recommendation class IIa or IIb for a CRT depending on their NYHA functional class. Both 
these recommendations were provided with an evidence level C. There was no mention of 
upgrading from a previous device. 17 The ESC EHRA (2013) guidelines also provided a class IIa 
recommendation for a CRT to avoid RV pacing dependence. However, a Class I recommendation 
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was provided for upgrading to a CRT from either a pacemaker or an ICD if the patient had a high 
percentage of ventricular pacing. 27 The ESC HFA guidelines released three years later provided 
the opposite recommendations class I for prophylactic insertion of a CRT device to avoid 
deterioration of LV function with chronic pacing and a IIb for an upgrade from a previous 
device.8 While the Canadian guidelines released the following year lowered the recommendation 
for patients with a high degree of AV block likely to be RV pacing dependent to a class IIb. 87 
 
In CRT Survey II 23% of patients were upgrade from a previous device (pacemaker of ICD). Of 
these patients 44% had AV block type I and II and 39% had the clinical indication of 
implantation of a CRT -pacemaker indication and expected RV pacing dependence. These 
findings suggests that despite the imprecise nature of  the evidence and the guidelines, implanters 
continue to appreciate the value of avoiding RV pacing either by prophylactically inserting a 
CRT device or by later upgrading to one. In our survey, patients upgraded from a previous device 
and those implanted de novo were equally frequently successfully implanted and the patients had 
similar complication rates. 116 Interestingly, these similar successes and complication rates were 
present despite the upgraded patient population being older, having greater co-morbidities and 
worse heart failure disease state. 
 
The decision to prophylactically implant a CRT or later upgrade is difficult to make due to the 
limited evidence available in this area.  Patients with a previous pacemaker were excluded from 
the landmark CRT trials (expect for MUSTIC-AF and RAFT) and, therefore, trial evidence to 
support upgrading to a CRT remains lacking.  Registry data from both Denmark and the US 
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reported more complications with patients who were upgraded from a previous device compared 
with those implanted de-novo. 39, 117 Furthermore, an observational study comparing 233 patients 
with an upgraded CRT device found that these patients had inferior long term outcomes 
compared with those implanted de-novo. 118 In contrast, a large meta-analysis analysis of 21 363 
patients upgraded to a CRT found that they had similar all-cause mortality to patients implanted 
de-novo. 119 Therefore, the evidence is unclear as to what is the best treatment for patients with 
AV block who are likely to be have a high degree of RV pacing. Fortunately, there is currently a 
RCT ongoing called the BUDAPEST-CRT upgrade study, which will randomize patients to a 
CRT-D or ICD upgrade. Hopefully, this study will be able to help guideline task forces to 
determine whether CRT should be upgraded prophylactically in these patients or whether they 




4.8 Factors Influencing Health Care Resources Utilization  
We split the 42 countries participating in CRT Survey II into three groups according to how high 
their current health expenditure was per capita: high (3493 patients), medium (6355 patients) and 
low (848 patients) and compared these three groups. The countries with the lowest health care 
expenditure were more likely to implant CRT in patients that had strong guideline 
recommendations for implantation such as symptomatic heart failure – NYHA Class II-IV (99% 
vs. 95%, p<0.001), LVEF≤ 35% (95% vs. 84%, p<0.001), sinus rhythm (81% vs 67%, p<0.001), 
QRS duration ≥150 ms (73% vs. 66%, p<0.001) and LBBB (84% vs. 74%, p<0.001). Patients 
with all the above characteristics have a recommendation class I, evidence level A indication for 
CRT in both the ESC CRT guidelines from the HFA and EHRA. 8, 27 Overall, 78% of patients 
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were implanted with indications with recommendation class I, evidence level A in the lowest 
healthcare spending per capita countries vs. 56 % in the highest spending group. These countries 
were also less likely to implanted patients under lower recommendation class such as those with 











The countries with the lowest health care expenditure were also less likely to implant CRT in 
elderly patients (median age 65 years vs. 72 year, p<0.001 with 15% vs. 39%, p<0.001 of patients 
≥75 years of age), thereby perhaps actively limiting these devices to younger patients. The 
percentage of females implanted with device on the other hand was high in the low expenditure 
countries (31% vs. 25%, p<0.001). This finding fits with the conclusion of paper 4 that women 
are more likely to be implanted under strong recommendation class compared with men. The 
ratio of CRT-P to CRT-D implants were similar in all three of the spending groups with CRT-P 
Regarding  CRT indication  with  different  recommendation  strength  in  the  ESC EHRA  and  ESC
HFA guideline  such  as upgrades  from  a previous  device  and pacemaker indication  with  expected
RV pacing dependence, these  indications were also  much  less  frequent  in  countries  with  the
lowest  expenditure  on health  care (14% vs.28%, p<0.001 and  11% vs. 27%, p<0.001
respectively), thereby  suggesting that the  high  guideline  adherence  may  not  be related  to
compliance  but rather to the  limited  resources  to explore  indications with  less  strong guideline
recommendations. Our data also  suggest  that  countries  with  lower  health  care expenditure  are
limiting  CRT devices not only  to those  with  the  strongest recommendation class but also to the
most  symptomatic  patients, with  56% vs.  45%, p<0.001 having  been hospitalized  for  HF during
the  past year  and 61% vs.  56%, p<0.001 being  in  NYHA Class  III or IV.
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percentages being 28% in the lower health care spending group, 30% in the moderate and 32% in 
the highest spending group.  
 
We have also analysed our data to compare countries with a higher CRT implantation rate per 
capita (≥ 0.011%, 13 countries) compared to those with a lower implantation rate (<0.011%, 29 
countries). Again we found differences in percentage of the following characteristics associated 
with high recommendation class in ESC guidelines. Countries with the lowest implantation rates 
had greater percentage of patients who had strong guideline recommendations for implantation 
such as symptomatic heart failure – NYHA Class II-IV (98% vs. 95% p<0.001), LVEF≤ 35% 
(89% vs. 85%, p<0.001), sinus rhythm (71% vs 68%, p<0.001), QRS duration ≥150 ms (75% vs. 
63%,p<0.001) and LBBB (78% vs. 73%, p<0.001). However these differences between the 
groups were not as large as those seen in the healthcare expenditure analysis. Overall, 66 % of 
patients were implanted with indications with recommendation class I, evidence level A in the 
countries with lower implantation rate vs. 56 % in the countries with higher implantation per 
capital group.  
 
The countries with the lowest implantation rates also had slightly lower rates of implantation of 
patient groups with weaker recommendations (AF, 25% vs. 27%, p<0.001).  Regarding the 
indications with varying degrees of recommendation in the EHRA and HFA guidelines, they 
were slightly lower for the upgrades (21 % vs. 26%, p<0.001)  and similar in the patients 





Median age of the patients was lower for the countries with the lowest implantation rate (68 years 
vs. 72 years, p<0.001) and so was the percentage of female patients (23% vs. 25%, p=0.144). Our 
data suggest that European countries with a lower implantation rate may be more likely to limit 
CRT implantation to patients with the strongest recommended indication for CRT.  
 
Comparing centres that where only funded by public healthcare with those totally or partially 
privately funded there was no major differences in  NYHA Class II-IV (97% vs. 97%, p=0.301),  
LVEF≤ 35 (87% vs. 87%, p=0.081), sinus rhythm (69% vs 69%, p=0.444), QRS duration ≥150 
ms (69% vs. 69%,p=0.162) and LBBB (75% vs. 75%, p=0.562). Overall 61 % of patients 
implanted in centres only funded by public healthcare were implanted with indications with 
recommendation class I, evidence level A vs. 62 % implanted in centres totally or partially 
privately funded. Thus, how the centre was funded did not appear to highly influence how many 
patients are implanted under the strongest guideline recommendations. 
 
Regarding the indications with weaker recommendation classes such as patient with AF, there 
was also no difference (26% vs. 25%, p=0.443).  The indications with varying degrees of 
recommendation in  the EHRA and HFA guidelines were slightly lower in the publically funded 
group  (upgrades 23% vs. 26%, p<0.001  and patients implanted with pacemaker indication and 
high degree of RV pacing dependence 22% vs. 28%, p<0.001). Median age of the patients (70 
years vs. 71 years, p=0.051) and percentage females (24% vs. 24%, p=0.683) were also similar. 
Again percentage of CRT-P and CRT-D were similar in the two groups. Our data suggest that in 






     
  
   






CRT is an example of ‘supply-sensitive care’ where the supply of a specific resource has also an 
influence on the implantation rates. However, CRT is also an example of ‘preference-sensitive 
care’ where different choices are available for patient care that include different risks and benefits  
and thus patients’ attitudes towards the treatment is likely to vary. 124 Such preference could 
influence the implantation of a CRT-P vs. a CRT-D or CRT implantation vs. intensifying optimal 
medical therapy. In preference-sensitive care the correct CRT implantation rate reflects the 
choice of correctly informed patients.  124  
 
Global comparison analysis of heart failure treatment has been performed in the ASCEND-HF, 
ASTRONAUT trial and PARADIGM- HF trials. All these comparisons showed large differences 
in percentage of HF patients that were implanted with CRT and ICD/CRT-D between continents 
(table 14, 15 and 16). 125 126, 127  
CRT Survey  II has thus  demonstrated  unwarranted  variation  in  CRT delivery. The  term
‘unwarranted variation’  has been coined  to describe  variations  in  medical  practice  between
geographical  regions  or provider  groups  (hospitals  or  physicians)  that  cannot  be explained by the
patient’s morbidity,  risk  factors  or preferences. 121, 122 Such ununiformed  delivery  of healthcare
demonstrated  in CRT Survey  II is  unfortunately  not unique; previous  studies  have  shown  that
patients’ morbidity  is  not the  main  determinant  of  healthcare  utilization  and  expenditure ; rather, it
is geography.123,  124 121 Previous  evidence  suggests that the problem  of unequal  health  delivery  is
not only  related  to differences in  individual  countries  but  that  there also exists  uneven healthcare
delivery  between  centres  and physicians  for similar  medical  conditions. 121 In Europe,  a
collaboration  has  been initiated  to understand  and address these  variations  in  medical  practice –
the  European  Collaboration  for  Healthcare  Optimization. 124
76 
Table 14- Global Variation in ASCEND-HF Trial, 
Table adapted from ASCEND-HF  trial 2013.126 
Table 15- Geographic Variations in the ASTRONAUT Heart Failure Trial 
Adapted from ASTRONAUT trial. 2015  127 
Table 16- Geographic Variations in the PARADIGM-HF Heart Failure Trial 
Adapted from PARADIGM-HF 2016.125 
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An important explanation for the large variations in CRT delivery demonstrated in CRT Survey 
II and worldwide is that these devices are not reimbursed in all countries. Implementation of CRT 
requires a large infrastructure to select, implant and follow-up CRT devices and thus implantation 
rates per capita are usually higher in well-resourced healthcare systems. 126 
 
4.9  CRT Response and Underutilization of CRT  
This PhD thesis focuses on patient selection for CRT. However, in order for a CRT device to 
result in morbidity and mortality improvement it is essential that the device is optimally 
implanted and that the patient is adequately followed up. Further discussion on this topic is 
beyond the scope of this PhD.  
 
The main obstacle to a successful treatment with CRT remains underuse. A study in Sweden 
showed that although 25–30% of patients with heart failure had a strong indication for a CRT 
device, only 7% had a device implanted. 128 Factors associated with underuse included inadequate 
referral, female sex, and being older than 75 years. 128 Therefore, not only is it important to select 
the correct patient for a CRT, it is also essential that awareness of the benefits of this device are 









The ability of a survey to describe practice is related to the strength of its methodology, its 
representativeness and size. Although the number of patients enrolled in CRT Survey II was 
large, there were substantial differences in recruitment between countries. Overall, we estimate 
that about 11% of patients implanted with CRT devices in participating countries during the 
recruitment period were enrolled in the survey. We cannot assess the degree of selection bias in 
the choice of enrolled patients. Although we requested enrolment of consecutive patients, it was 
not possible to verify this, and sites may have been less likely to report unsuccessful implants or 
cases with a poor outcome. It is also possible that centres may have been less likely to report 
implants in patients without class I or II guideline indications, resulting in low reported numbers 
with class III indications.  Furthermore, the eCRF was designed to be as user-friendly as possible 
in order to maximize the number of patients enrolled and the interpretation of questions was up to 
the discretion of the investigator. 
 
Finally, as in all non-mandatory registries or surveys we are only able to comment on the patients 
who received a CRT device. We do not know how many patients with a class I indication did not 
receive a CRT device.  It should also be noted that in our comparison of CRT Survey I and CRT 
Survey II the eCRFs were not identical; furthermore, CRT Survey I included patient follow-up 
while CRT Survey II did not. CRT Survey I contains far fewer patients, and although the same 




Although the survey appears to demonstrate that evidence defines guidelines, which then in turn 
define practice, we cannot firmly conclude that this is the case. We can merely state that these 



















In patients with indications for CRT where there is firm evidence of treatment benefit, the 
international guidelines all provide strong recommendations for this treatment. However, in 
patients where the evidence of effect of CRT is limited, such as those with non-LBBB, atrial 
fibrillation or a high degree of AV block and presumed RV pacing dependence,  international 
guidelines provide imprecise and inconsistent recommendations.  
 
In CRT Survey II we demonstrated that most patients implanted with a CRT device had a 
guideline recommendation class I indication for a CRT and therefore adherence to CRT 
guidelines in Europe is high.  However, particularly for the patients with CRT indications where 
there is limited evidence of benefit and international recommendations are inconsistent, 
variations in European practice are evident.  
 
Such variations in clinical practice were also found in the choice of device type (CRT-P vs.  
CRT-D), which is also an area where trial evidence is lacking and international guidelines 
provide imprecise recommendations. We demonstrated large variations in percentage of CRT-P 
vs.  CRT-D in our cohort between patient subgroups and between countries.  
 
We also found that countries with both the lowest healthcare expenditure and the lowest 
implantation rate per capita were more likely to implant patients with indications associated with 
strong recommendation classes. These findings suggest that this high guideline adherence may 
not be related to compliance but rather to the limited resources to explore indications with less 
strong guideline recommendations.  Such limitations of CRT implantations to patients with 
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strong indications were also evident in certain patient subgroups including women and younger 
patients.  
 
These variations in CRT practice are likely to decrease when the data from trials on patient with 
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Errata 
Page 34 Incorrect number: “CRT-D (n=7449)”. Text should read: “CRT-D (n=7467)” 
Page 47 Misspelling: “should be considered to weight in favour of” – corrected to “should be 
considered to weigh in favour of” 
Page 68 Incorrect word: “73% of patients had non-LBBB” – corrected to “73% of patients 
had LBBB” 
Page 72 Incorrect words: “expected high degree of AV block” – corrected to “expected RV 
pacing dependence” 
Page 75 Misspelling: “hospitals of physicians” – corrected to “hospitals or physicians” 
Paper III, Page 919 Incorrect number: “the cohort of 7305 patients”. Text should read: “the 
cohort of 7246 patients” 
Paper III, Page 921 Table 1 Incorrect number: “CRT-D (n=7449)” should read “CRT-D 
(n=7467)” 
Paper IV, Page 4 Incorrect word: “implanted under other indications” – corrected to 
“implanted under Level I indications” 
Paper IV, Page 9 Incorrect numbers: “4891 were de novo implantations, 493 were upgrades” 
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Indications for Cardiac Resynchronization Therapy
A Comparison of the Major International Guidelines
Camilla Normand, BM BCH,a,b Cecilia Linde, MD, PHD,c Jagmeet Singh, MD, PHD,d Kenneth Dickstein, MD, PHDa,b
ABSTRACT
OBJECTIVES This study compares and contrasts the recommended indications for cardiac resynchronization therapy
(CRT) according to the most recent guidelines from international cardiology societies.
BACKGROUND CRT has been shown to reduce morbidity and mortality in selected patients with systolic heart failure.
Cardiology societies provide guidelines regarding the indications for CRT. As evidence evolves, it is challenging for the
guideline committees to review the impact of newer evidence in a timely fashion.
METHODS Six of the most recent international guidelines providing recommendation concerning CRT implantation
ranging from 2011 to 2017 were reviewed. These included guidelines from 2 European, 1 North American, 1 Canadian, and
1 Australian/New Zealand societies and the National Institute for Health and Care Excellence guidelines, specific to the
United Kingdom.
RESULTS Although international societies provide consistent recommendations for most CRT indications, differences
are found in recommendations for several important patient populations. Specifically, divergent recommendations exist
regarding QRS duration, bundle branch morphology, patients in atrial fibrillation, choice of device type (CRT pacemakers
vs. CRT defibrillators), and selected patients who are likely to be dependent on right ventricular pacing. The timing of
publication of specific guidelines appears to play an essential role in explaining these disparities.
CONCLUSIONS Despite general consistency in international guideline recommendations, there remain certain patient
populations for whom there are variations in recommendations concerning eligibility for CRT and selection of the most
appropriate device in the individual patient. (J Am Coll Cardiol HF 2018;6:308–16) © 2018 by the American College of
Cardiology Foundation.
T he benefits of cardiac resynchronizationtherapy (CRT) have been firmly establishedin heart failure (HF) patients who remain in
New York Heart Association (NYHA) functional clas-
ses II and III, despite optimal medical therapy with
a wide QRS complex and reduced left ventricular
ejection fraction (LVEF) (#30% to 35%) (1–7).
This review compares and contrasts the most
recent international guidelines for CRT implantation
from 2011 to 2017. It includes guidelines from 2
European, 1 North American, 1 Canadian, and
1 Australian/New Zealand society. Also included are
the National Institute for Health and Care Excellence
(NICE) guidelines, specific to the United Kingdom.
Details of these guidelines are outlined in Table 1.
The American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) guidelines
for the management of HF published in 2013 were
harmonized with the ACCF/AHA/Heart Rhythm Soci-
ety (HRS) 2012 focused update of the 2008 guidelines
for device-based therapy of cardiac rhythm abnor-
malities (8). For simplicity, these documents were
considered together and referred to as the ACC/AHA/
HRS guidelines. Furthermore, since publication of the
2013 guidelines, several focused updates of HF have
been published by ACC/AHA/Heart Failure Society of
America (HFSA). These updates do not propose
changes to CRT recommendations and, therefore, will
not be discussed further (9,10). HFSA produced their
latest CRT recommendations in their 2010 guidelines
and 2011 guideline update (11,12). They have since
been involved in publication of the above-mentioned
focused updates and collaborated with ACC/AHA/
HRS in both their 2012 focused update on CRT and the
ACCF/AHA 2013 guidelines. We have, therefore,
decided not to include the 2010 HFSA guidelines in
the review as these no longer represent the latest
recommended HF treatments from the HFSA.
Guideline recommendations are based on the
inclusion criteria in randomized controlled studies
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and their year of publication (Online
Table 1) (13). These criteria included severity
of HF despite optimal medical therapy,
reduced LVEF, electrical dyssynchrony, and
atrial rhythm.
GENERAL OVERVIEW OF THE
GUIDELINES CONSTRUCTION
LEVEL OF RECOMMENDATIONS AND
GRADING OF EVIDENCE. The 2 European
Society of Cardiology (ESC) guidelines and
the ACC/AHA/HRS guidelines use similar pre-
defined scales to grade their recommen-
dations and levels of evidence, with
recommendations ranging from Classes I to
III and evidence levels from A to C. Classes of
recommendation and levels of evidence used
in the ESC guidelines are presented in Online
Tables 2A and 2B (14,15).
Regarding the recommendation cate-
gories, rather than providing numerical
values, the Canadian Cardiovascular Society
(CCS) uses only text such as: “is recom-
mended, should be considered, may be considered,
and is not recommended.” For simplicity of com-
parison and presentation, we have divided the text
categories into I, IIa, IIb, and III, respectively.
Furthermore, rather than use evidence levels A to C,
the Canadian guidelines grade the quality of evidence
as “High,” “Moderate,” “Low,” or “Very Low,” ac-
cording to the Grading of Recommendations
Assessment, Development, and Evaluation
(GRADE) standards (16,17). These are shown in Online
Table 3.
The Australian guidelines use the National Health
and Medical Research Council (NHMRC) guidelines,
“A Guide to the Development, Implementation and
Evaluation of Clinical Practice Guidelines” (18), to
grade their evidence levels and recommendations. In
these guidelines, the level of evidence is stated
numerically and the grade of recommendation
alphabetically, which is the reverse of the other
guidelines reviewed. These are shown in Online
Tables 4 and 5.
The NICE guidelines, on the other hand, do not
provide levels of evidence or grades of recommen-
dations. They are different in presentation as they
specifically address which type of device therapy is
indicated (CRT-pacemaker [CRT-P], CRT-defibrillator
[CRT-D], or implantable cardioverter-defibrillator
[ICD]) based on NYHA functional class and QRS
duration and morphology.
COMPARISON OF GUIDELINES
RECOMMENDATIONS FOR CRT THERAPY
IN PATIENTS IN SINUS RHYTHM
PATIENTS WITH LEFT BUNDLE BRANCH BLOCK. Table 2
compares recommendations for patients with left
bundle branch block (LBBB). In patients with LBBB
and a QRS duration >150 ms, all guidelines reviewed
provide strong recommendations for CRT.
For a QRS duration between 120 and 129 ms, there
are inconsistencies particularly between the 2 ESC
associations. ESC European Heart Rhythm Associa-
tion (EHRA) (2013) provides a Class I recommendation
(“is recommended”), whereas the ESC Heart Failure
Association (HFA) (2016) states a Class III recom-
mendation (“is not recommended”)! The CCS guide-
lines (2017) also clearly state that CRT should not be
used for patients with QRS <130 ms. QRS duration
with the cutoff set to >120 ms in the EHRA guidelines
reflects the inclusion criteria in many trials such as
COMPANION (Comparison of Medical Therapy, Pac-
ing, and Defibrillation in Heart Failure) and CARE-HF
(Cardiac Resynchronization—Heart Failure) (3,7). Af-
ter publication of the ECHO CRT study, which indi-
cated increased cardiovascular mortality with CRT in
patients with QRS <130 ms, the HFA 2016 and CCS
2017 guidelines set the cutoff for CRT to >130 ms (19).
PATIENTS WITH NON-LBBB. For patients with non-
LBBB, ACC/AHA/HRS and ESC guidelines agree that
if a patient has a QRS duration >150 ms and is in
NYHA functional class III or ambulatory IV, then a
CRT “should be considered” (Class IIa). CCS provides a
“may be considered” (Class IIb) recommendation for
the same indication (Table 3).
There is considerable inconsistency in the guide-
lines for patients with non-LBBB and a QRS <150 ms,
with recommendations varying from Classes IIb to III.
The CCS guidelines do not provide a formal recom-
mendation for this patient group; instead, they sim-
ply state that there is no clear evidence of benefit
with CRT among patients with QRS duration <150 ms
because of non-LBBB conduction. Furthermore, the
levels of evidence provided for this patient group
vary even for similar classes of recommendation.
AUSTRALIA (2011). The Guidelines for the Preven-
tion, Detection and Management of Chronic HF
in Australia, published by the National Heart
Foundation of Australia and the Cardiac Society
of Australia and New Zealand in 2011, do not distin-
guish between LBBB and non-LBBB when providing
their recommendations for CRT in patients in sinus
rhythm (20).
ABBR EV I A T I ON S
AND ACRONYMS









HF = heart failure
ICD = implantable
cardioverter-defibrillator
LBBB = left bundle branch
block
LV = left ventricular
LVEF = left ventricular ejection
fraction
NYHA = New York Heart
Association
RBBB = right bundle branch
block
RV = right ventricle
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NICE GUIDELINES (2014). NICE guidelines recom-
mend placement of a CRT device in patients with
LBBB with a QRS duration $120 ms and in those with
non-LBBB, if the QRS duration is $150 ms for patients
in NYHA functional classes II, III, and IV. This is
generally consistent with other guidelines reviewed.
For patients with non-LBBB who have a QRS be-
tween 120 and 149 ms, NICE guidelines only recom-
mend placing a CRT pacemaker without ICD in
patients in NYHA functional class IV. In contrast to
the other guidelines reviewed, NICE guidelines do not
specify that NYHA functional class IV patients must
be ambulatory. They also recommend implantation in
NYHA functional class I provided the patients have a
QRS >150 ms. NICE guidelines also differ from most
of the other guidelines reviewed in that they provide
clear guidance on whether to implant a CRT-P or a
CRT-D. However, in contrast to the other guidelines,
NICE does so without providing classes of recom-
mendation or levels of evidence.
SUMMARY OF INTERNATIONAL RECOMMENDATIONS
FOR LBBB AND NON-LBBB. All cardiac societies’
guidelines reviewed agree that patients with
LBBB and a QRS duration $150 ms should be offered a
CRT device provided they are in NYHA functional
class III.
There also appears to be general consensus among
the international guidelines for CRT implantation in
patients with LBBB and a QRS duration $150 ms in
NYHA functional class II and ambulatory IV.
In LBBB patients with narrower QRS duration (120
to 149 ms), there is less agreement, especially in pa-
tients with a QRS duration <129 ms and NYHA func-
tional class II symptoms. The most striking
discrepancy is between the ESC guidelines, with
EHRA providing a Class I recommendation for QRS
duration between 120 and 129 ms and HFA class III.
With non-LBBB there is a wide discrepancy among
the guidelines, again especially concerning the nar-
rower QRS and patients with less symptomatic HF,
due to year of publication. Since 2011, increasing ev-
idence has shown better prognosis for CRT implan-
tation in LBBB patients versus non-LBBB patients in
subgroup analysis of randomized control trials
(21,22). These analyses have greatly influenced the
guidelines. LBBB was not a selection criteria in any of
TABLE 1 Recent International Guidelines on CRT Implantation Recommendations and Indications
Society Guideline (Ref. #) Year
ESC Heart Failure Association Guidelines for the diagnosis and treatment of acute and
chronic HF (15)
2016
ESC European Heart Rhythm Association Guidelines on cardiac pacing and CRT (14) 2013
American College of Cardiology Foundation/
American Heart Association
Guidelines for the management of HF (37) 2013
Canadian Cardiovascular Society Comprehensive update of the Canadian Cardiovascular Society
Guidelines for the Management of HF (16)
2017
National Heart Foundation of Australia and
Cardiac Society of Australia and New Zealand
Update to guidelines for the prevention, detection and
management of chronic HF in Australia, 2006 (20)
2011
National Institute of Health and Care Excellence ICD and CRT for arrhythmia and HF (38) 2014
CRT ¼ cardiac resynchronization therapy; ESC ¼ European Society of Cardiology; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator.
TABLE 2 Comparison of Recommendations for LBBB
Guideline (Year)













ESC HFA (2016)* I, A I, A I, B I, B III, A III, A
ESC EHRA (2013) I, A I, A I, B I, B I, B I, B
ACC/AHA/HRS (2013) I, A I, B IIa, B IIa, B IIa, B IIa, B
CCS (2017) I, High I, High I, High I, High III, Moderate III, Moderate
Australian Guidelines (2011) A A A
NICE (2014) CRT-P or CRT-D† CRT-D CRT-P or CRT-D† CRT-D CRT-P or CRT-D† CRT-D
Values are Class of Recommendation, Level of Evidence, unless otherwise indicated. Australian guidelines provide only grade of recommendation (A), not evidence level for
these recommendations. NICE guidelines provide guidance on type of device rather than recommendation or evidence level. *The ESC HFA guidelines do not specify NYHA
functional class, rather they state that the guidelines refer to symptomatic patients with heart failure. †Not for NYHA functional class IV.
ACC/AHA/HRS ¼ American College of Cardiology/American Heart Association/Heart Rhythm Society; CCS ¼ Canadian Cardiology Society; CRT-D ¼ cardiac resynchronization
therapy-defibrillator; CRT-P ¼ cardiac resynchronization therapy-pacemaker; ESC EHRA ¼ European Society of Cardiology European Heart Rhythm Association; ESC HFA ¼
European Society of Cardiology European Heart Rhythm Association; LBBB ¼ left bundle branch block.
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the CRT trials; however, a wide QRS duration in these
trials (average, 168 ms) in CARE-HF, MUSTIC, MIRA-
CLE, and COMPANION trials was most often accom-
panied by LBBB (1–3,7). In contrast, in the later
trials including mild to moderate heart failure,
average QRS durations were smaller at 158 ms, and in
these subgroups, analyses revealed a greater benefit
in cases of LBBB than in other bundle branch mor-
phologies (21,22). It should be noted, however, that
there are mixed views of the value of LBBB in deter-
mining response to CRT. A meta-analysis of 5 ran-
domized trials showed QRS duration to be a powerful
predictor of CRT effect with QRS morphology not
providing any additional information about clinical
response (23).
GUIDELINE RECOMMENDATIONS FOR
PATIENT GROUPS WITH LESS
CONVENTIONAL INDICATIONS FOR CRT
ATRIAL FIBRILLATION. The two ESC and the ACC/
AHA/HRS guidelines provide a Class IIa recommen-
dation for CRT implantation in patients with systolic
HF and AF (Table 4). CCS provides a “may be consid-
ered” (Class IIb) for these patients. European guide-
lines specify that patients must have LVEF #35% and
NYHA functional class III or IV HF. Again, the ESC
associations disagree on QRS duration. The ACC/AHA/
HRS and CCS guidelines simply state that eligible
patients must otherwise qualify for a CRT device.
The Australian guidelines do not discuss patients
with AF.
There is, therefore, general consistency in the
guidelines that patients with AFmay be considered for
a CRT but that the evidence for this is limited. Most
randomized control trials of CRT excluded patients
with AF, and those trials that did include patients with
AF were small (Online Table 1) (6,24,25). This is un-
fortunate as 10% to 50% of patients with moderate or
severe HF have concomitant AF (24,26). In the
guidelines that provide recommendations for CRT in
patients with AF there is consensus that ventricular
rate must be adequately controlled by pharmacologic
intervention or atrioventricular nodal ablation in
order to ensure a high degree of CRT pacing (27).
CONVENTIONAL PACEMAKER INDICATION AND
HF. In patients with systolic HF and conventional in-
dications for pacemaker that are likely to be dependent
on chronic right ventricular (RV) pacing, the strongest
recommendation comes from the ESC. HFA guidelines
(2016) provide a Class I recommendation, Level of
Evidence: A for patients with an indication for ven-
tricular pacing and high-degree atrioventricular block
and include patients with AF. These guidelines were
published after the publication of the BLOCK-HF trial,
which showed that biventricular pacing was superior
to RV pacing in patients with HF and atrioventricular
block (28). The EHRA and ACC/AHA/HRS guidelines
provide a Class IIa recommendation. The ACC/AHA/
HRS guidelines specify that the degree of anticipated
RV pacing must be >40%. This figure is based on the
DAVID (Dual Chamber and VVI Implantable Defibril-
lator) trial, which suggested a worse outcome in pa-
tients who were paced at >40% (29). None of the other
TABLE 3 Comparison of Recommendations for Non-LBBB
Guidelines (Year)













ESC HFA (2016)* IIa, B IIa, B IIb, B IIb, B III, A III, A
ESC EHRA (2013) IIa, B IIa, B IIb, B IIb, B IIb, B IIb, B
ACC/AHA/HRS (2013) IIa, A IIb, B IIb, B III, B IIb, B III, B
CCS (2017) IIb, Low IIb, Low III, Moderate III, Moderate
Australian Guidelines (2011) A A A
NICE (2014) CRT-P or CRT-D† CRT-D CRT-P‡ CRT-P‡
Values are Class of Recommendation, Level of Evidence, unless otherwise indicated. Australian guidelines provide only grade of recommendation (A), not evidence level for
these recommendations. NICE guidelines provide guidance on type of device rather than recommendation or evidence level. *The ESC HFA guidelines do not specify NYHA class,
rather they state that the guidelines refer to symptomatic patients with heart failure. †Not for NYHA functional class IV. ‡Only for NYHA functional class IV.
Abbreviations as in Table 1 and 2.






With Reduced LVEF and
Symptomatic HF
ESC HFA (2016) IIa, B I, A
ESC EHRA (2013) IIa, B IIa, B
ACC/AHA/HRS (2013) IIa, B IIa, C
CCS (2017) IIb, Low IIb, Moderate
Values are Class of Recommendation, Level of Evidence.
Abbreviations as in Tables 1 and 2.
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guidelines specify the exact degree of anticipated
pacing for this recommendation.
The CCS guidelines provide a Class IIb recom-
mendation for patients who require chronic RV pac-
ing in the setting of HF symptoms and reduced LVEF,
with moderate quality evidence. Interestingly, these
guidelines, like the HFA guidelines, were produced
after BLOCK-HF. However, HFA guidelines provide a
recommendation level I and CCS only a level IIb.
This indication is not discussed in the Australian
guidelines.
Choice of device—a conventional pacemaker or a
CRT—is a rapidly evolving issue, and guidelines con-
cerning the patient categories likely to benefit from
CRT are not yet clearly defined. Evidence suggests that
chronic RV pacing in patients with symptomatic HF or
left ventricular (LV) dysfunction may lead to deterio-
ration in LV systolic function accompanied by an
increase in LV volumes (30,31). Although the compli-
cation rate is greater with an increasing number of
leads implanted, a later upgrade from a permanent
pacemaker to a CRT is also associated with added risk.
PATIENTS WITH HF AND AN ICD INDICATION. The
ESC EHRA and CCS guidelines provide a Class I
recommendation for a CRT-D in patients requiring an
ICD if a CRT is indicated. The HFA guidelines state
that if a patient is due to receive an ICD and has a QRS
duration between 130 and 149 ms, a CRT-D should be
considered, and if the QRS is $150 ms, a CRT-D is
recommended. The Australian guidelines provide a
grade A recommendation for CRT for patients
requiring an ICD in NYHA functional class II, provided
they are in LBBB with a QRS $150 ms and an
LVEF #30%. The NICE guidelines provide clear
guidance concerning the choice between CRT-P and
CRT-D. If an ICD is required in a patient with over-
lapping CRT indications, perhaps an unnecessary
later upgrade from an ICD to CRT-D could be avoided.
CRT-P VERSUS CRT-D. EHRA guidelines also provide
guidance as to whether to implant a CRT-P or a
CRT-D. EHRA guidelines favor CRT-P implantation in
patients with advanced HF, severe renal insufficiency
or dialysis, and other major co-morbidities including
frailty and cachexia. CRT-D, on the other hand, is
recommended if the life expectancy is >1 year in pa-
tients with NYHA functional class II, ischemic heart
disease, and no major co-morbidities. HFA guidelines
state that, if the primary reason for implanting a CRT
is to improve prognosis, most evidence lies with
CRT-D in patients with NYHA functional class II and
for CRT-P for patients in NYHA functional classes III
to IV. If the primary reason for implanting the device
is relief from symptoms, HFA guidelines propose that
the clinician should choose between a CRT-P and a
CRT-D, as he/she considers appropriate. CCS guide-
lines suggest that a CRT-P be considered in patients
who are not candidates for ICD therapy, such as those
with a limited life expectancy because of significant
comorbidities. NICE guidelines also clearly provide
advice concerning the choice of device.
No randomized studywas powered to compare CRT-
D versus CRT-P, but one study compared these devices
to optimalmedical therapy (7). It is likely to be this lack
of evidence which leads most associations to leave the
choice of device to the implanting physician.
UPGRADES. HFA guidelines state that patients who
have received a conventional pacemaker or an ICD and
developworsening HF andwho have a high proportion
of RV pacing may be considered for an upgrade to a
CRT. This is a Class IIb recommendation with Level of
Evidence: B. EHRA guidelines, on the other hand,
provide a Class I recommendation with a Level of
Evidence: B for an upgrade from both a pacemaker and
an ICD, providing the patient has a high degree of
ventricular pacing and is in NYHA functional class III
or ambulatory IV. The ACC/AHA/HRS guidelines pro-
vide a recommendation Class IIa, Level of Evidence: C,
for patients with LVEF #35% who are undergoing
implantation of a replacement device with anticipated
requirement for significant (>40%) ventricular pacing.
The CCS guidelines do not provide recommenda-
tions for upgrading previous devices, and there is no
mention of upgrades in the Australian guidelines.
CRT survey II found that 28% of CRT devices
implanted were upgrades from either a permanent
pacemaker or an ICD (35). Despite this large number
of upgrades implanted, the evidence in this area is
limited to small trials and observational studies. Up-
grades have become increasingly common in view of
heightened awareness that RV pacing >40% may
aggravate LV function and cause HF. It was demon-
strated that patients upgraded to CRT with prior RV
pacing respond to CRT at least as well as, if not better
than, HF patients eligible for CRT by wide QRS
complex (36).
NYHA FUNCTIONAL CLASS I. None of the ESC
guidelines, CCS, or Australian guidelines provide rec-
ommendations for patients in NYHA functional class I.
The ACC/AHA/HRS guidelines, on the other hand,
provide a Class IIb recommendation, evidence level C,
on condition that the patients have LBBB with a
QRS $150 ms, HF caused by ischemia, and an
LVEF #30% on guideline-directed medical therapy.
They do not recommend CRT implantation in NYHA
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functional class I patients if they do not have LBBB and
a QRS #150 ms, providing this indication with a Class
III recommendation. NICE guidelines recommend im-
plantation in patients with a QRS $150 ms in NYHA
functional class I, regardless of the morphology of the
bundle branch block. CCS guidelines state that there is
insufficient evidence to recommend CRT to patients
with NYHA functional class I status.
Thus, most of the guidelines do not discuss pa-
tients with NYHA functional class I. Those that do,
either provide a III recommendation or a weak
recommendation for a wide QRS. Although both the
MADIT CRT and REVERSE studies included NYHA
functional class I patients, the total number of these
patients included was small, and the subgroup anal-
ysis was not meaningful (4,5).
NARROW QRS. EHRA guidelines provide a Class III
recommendation, Level of Evidence: B, for a QRS
duration <120 ms; whereas the HFA provides a III
recommendation, Level of Evidence: A, for QRS dura-
tion <130 ms; and CCS clearly states that CRT should
not be used in patients with QRS duration <130 ms.
NICE guidelines clearly state that a CRT is not indicated
in NYHA functional class IV with a QRS <120 ms. The
other guidelines only provide guidance for patients
with QRS >120 ms rather than specifically mentioning
not to implant in cases with a narrower QRS.
There is increasing evidence that patients with a
narrow QRS do not benefit from a CRT device. The
Echocardiography CRT and the LESSER EARTH trials
were designed to compare effects of active versus
inactive CRT therapy in patients with a QRS >130 ms
and QRS>120 ms, respectively (19,32). Both trials were
stopped as they were deemed futile. Following the
publications of those trials, 2 meta-analyses have been
published showing that CRT implantation in narrow
QRS is associated with a poor prognosis (33,34).
AGE AND CO-MORBIDITIES. CCS guidelines state
that CRT-P should also be considered in patients who
are not candidates for ICD therapy because of limited
life expectancy and significant co-morbidities. EHRA
guidelines provide guidance on whether to place a
CRT-P or a CRT-D depending on the co-morbidities of
the patient. Remarkably, there is limited concrete
advice in the other guidelines regarding the impact
on clinical decision making of age and comorbidities
in the individual patient.
DISCUSSION
This review is the most currently available compari-
son of international guidelines on CRT. It demon-
strates areas of consistency and inconsistency in
recommendation for CRT.
POTENTIAL EXPLANATIONS AND CONSEQUENCES
FOR INCONSISTENCIES AMONG GUIDELINES. Guide-
line development is a rigorous process. Evidence pro-
duced by randomized control trials must be peer
reviewed and published before it is interpreted by the
guideline task forces and specific recommendations
are formed. Therefore, there is a time lag between
production of evidence and its incorporation into
guidelines, and some pivotal studies may, as a result,
only be available for the next guidelines. If these
guidelines are those of another society or association,
this will result in guideline inconsistencies. A recent
example is the inconsistency between the EHRA ESC
guidelines (2013), which recommended implantation
of CRT in appropriate patients with a QRS duration
>120 ms and the ESC HFA, published 3 years later,
which emphasized new evidence that emanated from
ECHO-CRT, showing no CRT benefit in otherwise
eligible patients with a QRS durations <130 ms (19).
When guidelines provide a Class IIa or IIb recom-
mendation, it reflects insufficient scientific evidence
and uncertainty concerning the efficacy of CRT in a
particular clinical scenario. In these situations, it is not
surprising that there may be different interpretations
between different guideline task forces. For example,
regarding permanent AF, some guideline committees
interpret the existing scientific evidence as supporting
the use of CRT in order not to withhold a potentially
beneficial therapy in a particular patient with perma-
nent AF and symptomatic HF. Whereas other com-
mittees may be less persuaded by the available
evidence which to date has not convincingly demon-
strated efficacy in this population.
The International Cardiology Societies reviewed
here appear to differ in the ways in which they eval-
uate the strengths and weaknesses of a study. This is
apparent by their choice of different grading systems
and also by the fact that the same evidence is graded
with different strengths. Most of the guidelines
reviewed provide guidance for a single country;
however, the ESC guidelines by EHRA and HFA pro-
vide recommendations for all 56 member states.
Applicability of the recommendations in all these
countries must therefore be considered by the task
forces. Furthermore, although all guideline taskforces
are well aware of the high initial costs of CRT im-
plantation, only NICE formally considers health eco-
nomics when providing their guidelines.
There are important consequences of these in-
consistencies in guidelines for patients, clinicians,
policy makers, and stakeholders. Clearly, the varia-
tions in recommendations, especially among soci-
eties responsible for the same health care
geographical area, such as ESC EHRA and ESC HFA,
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may contribute to some confusion among those
delivering the care.
Furthermore, these inconsistencies make it diffi-
cult to accurately assess CRT adoption rate in
different countries; therefore, identifying whether
appropriate and evidence-based patient care is being
delivered uniformly is challenging.
CLINICAL AND HEALTH POLICY IMPLICATIONS OF
THIS REVIEW. For clinicians and health care pro-
viders, demonstration of consistency across guide-
lines in this review is reassuring since it identifies
populations where there is agreement on CRT effi-
cacy. In contrast, the areas where this review identi-
fied inconstancies will serve to make clinicians less
enthusiastic about implanting a CRT in the patient
populations in which the evidence is insufficient.
This review should inform future clinical research
by highlighting the areas in which evidence is scarce
or open to interpretation. Areas which require more
research include CRT in patients with AF, non-LBBB,
and those dependent on RV pacing. The guidelines
are also inconsistent with regard to recommendation
for device upgrades and the choice of CRT-P versus
CRT-D in a particular patient.
Furthermore, considering the length of time
required to produce a complete update of the guide-
lines on HF, perhaps a sensible approach is to release
specific, focused updates on HF regularly, concen-
trating on areas where there is new evidence. Such
updates have been produced by several of the asso-
ciations reviewed.
Finally, this review encourages clinicians and
health care providers to consult the most recent in-
ternational guidelines as these guidelines may
include the most current evidence and contain the
most appropriate recommendations.
CONCLUSIONS
Generally, there is strong consistency in the inter-
national guidelines on CRT implantation. However,
there remain certain patient populations for whom
there are divergent recommendations considering
eligibility and selection of the most appropriate
device in a particular clinical scenario. Guidelines
are a documentation of best practice in a particular
environment at a certain moment in time and
clinicians, when reviewing these, should take
a critical view, especially as newer evidence accu-
mulates.
ADDRESS FOR CORRESPONDENCE: Dr. Camilla
Normand, Cardiology Department, Stavanger University
Hospital, Gerd-Ragna Bloch Thorsens gate 8, 4011 Sta-
vanger, Norway. E-mail: Camilla.normand@doctors.org.uk.
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cation. One of the explanations for these inconsistencies is likely
due to limited evidence of CRT benefit in these patients. This
review specifically identifies two important clinical areas in which
trial evidence is clearly lacking. These include management of
patients with atrial fibrillation and the choice of the most
appropriate device (pacemaker CRT vs. defibrillator CRT) for in-
dividual patients.
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Background Cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in appropriately selected patients with
heart failure and is strongly recommended for such patients by guidelines. A European Society of Cardiology
(ESC) CRT survey conducted in 2008–2009 showed considerable variation in guideline adherence and large
individual, national and regional differences in patient selection, implantation practice and follow-up. Accordingly,
two ESC associations, the European Heart Rhythm Association and the Heart Failure Association, designed a second
prospective survey to describe contemporary clinical practice regarding CRT.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
A survey of the clinical practice of CRT-P and CRT-D implantation was conducted from October 2015 to December
2016 in 42 ESC member countries. Implanting centres provided information about their hospital and CRT service and
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were asked to complete a web-based case report form collecting information on patient characteristics, investigations,
implantation procedures and complications during the index hospitalisation. The 11 088 patients enrolled represented
11% of the total number of expected implantations in participating countries during the survey period; 32% of
patients were aged ≥75 years, 28% of procedures were upgrades from a permanent pacemaker or implantable
cardioverter-defibrillator and 30% were CRT-P rather than CRT-D. Most patients (88%) had a QRS duration≥130ms,
73% had left bundle branch block and 26% were in atrial fibrillation at the time of implantation. Large geographical
variations in clinical practice were observed.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion CRT Survey II provides a valuable source of information on contemporary clinical practice with respect to CRT
implantation in a large sample of ESC member states. The survey permits assessment of guideline adherence and
demonstrates variations in patient selection, management, implantation procedure and follow-up strategy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure • Cardiac resynchronisation therapy • Demographics • Cardiac devices •
Health care utilisation •
Introduction
Randomised controlled trials (RCTs) and meta-analyses have
demonstrated that cardiac resynchronisation therapy (CRT)
reduces morbidity and mortality in appropriately selected patients
with symptomatic heart failure (HF), reduced left ventricu-
lar ejection fraction (LVEF) and QRS prolongation on the
electrocardiogram.1–7 Accordingly, the benefits of CRT for
such patients were accorded high levels of evidence and strong
recommendations in European Society of Cardiology (ESC) and
other international guidelines.8–12
The first ESC CRT survey, performed in 2008–2009 in 13 ESC
countries, demonstrated that implanters often extrapolated the
benefits of CRT to a broader population including patient groups
that were not well represented in RCTs, such as patients aged
>75 years or with a QRS duration <120ms, atrial fibrillation (AF),
or requiring an upgrade from an existing permanent pacemaker
(PPM) or implantable cardioverter defibrillator (ICD). The first
CRT survey also showed considerable regional and national differ-
ences in implantation practices.13 Since this survey was published,
several important modifications of ESC guideline recommenda-
tions concerning CRT indications have been made by both the
Heart Failure Association (HFA) and European Heart Rhythm
Association (EHRA).8,9,12 Therefore, these two ESC Associations
decided to collaborate and undertake a pan-European survey
designed to describe current clinical practice regarding implan-
tation of CRT devices in a larger sample of patients and greater
number of ESC member countries. CRT Survey II was not designed
to compare results with the first survey. There was limited over-
lap between the cohorts of the two surveys and substantial
differences in the data collected precluding valid comparison.
Lessons learned from conducting the first survey were used to
improve both the design and performance of CRT Survey II, which
involved many more countries. CRT Survey II provides insights
into contemporary clinical practice that is useful for patients,
clinicians, administrators, the pharmaceutical and device indus-
try as well as for parties who fund health care. Further analyses




























































The survey was designed as a joint initiative between the EHRA
and HFA. These two ESC Associations co-coordinated the sur-
vey with sponsorship from all five companies that manufacture
CRT devices as well as from several pharmaceutical and diag-
nostic companies (see Acknowledgements). The design and
rationale of CRT Survey II, along with the detailed contents
of the electronic case report form (eCRF) have been published
previously.14
A Scientific Committee was established, composed of equal num-
ber of members from each Association, together with non-voting
representatives from each of the five CRT device companies. The
Scientific Committee regularly monitored the progress of the sur-
vey and agreed on logistical adjustments during the period of data
collection.
Recruitment
The 47 ESC member states detailed in the 2014 EHRA White Book,
which provided information on the number of sites implanting CRT
and volume of activity in these countries, were invited to participate.15
Each participating ESC member country was represented by a National
Coordinator who was nominated by the President of their National
Cardiology Society. The National Coordinators were responsible for
obtaining national Institutional Review Board approval if required,
recruiting centres in their country and distributing information from
the Scientific Committee to their implanters. Of the 47 invited ESC
member countries, 42 agreed to participate. The National Coordi-
nators were requested to contact CRT implanters in their countries
and invite them to participate in the survey. Sites were then asked
to enter consecutive patients implanted with a CRT during the




For the first ESC CRT survey, the web-based eCRF used for data collec-
tion was developed by Institut für Herzinfarktforschung Ludwigshafen
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(IHF),16 which also conducted data management and statistical anal-
yses. Therefore, the Associations decided that IHF should support
similar functions for CRT Survey II. Together with the Scientific Com-
mittee, the IHF revised the eCRF, developed the statistical analysis plan
and was responsible for data monitoring and verification. No imputa-
tion for missing data was done. All percentages are relative to the total
number of patients with available information.
Each participating country had their data-points collected in the
eCRF benchmarked against the total cohort. The day-to-day opera-
tional running of the survey was conducted by Tessa Baak at Stavanger
University Hospital, University of Bergen, Norway.
Survey population
Any patient in the 42 participating countries was eligible for inclu-
sion if he/she was implanted with either a CRT with pacemaker func-
tion (CRT-P) or a CRT with an incorporated defibrillator (CRT-D).
This included both successful and unsuccessful implantations as well
as both de-novo CRT devices and upgrades from a PPM or ICD.
Generator replacements or revisions of existing CRT devices were
excluded as the survey was designed to capture only new CRT
implantations.
The one-time site questionnaire
Each implanting centre was requested to complete a one-time site
questionnaire, which provided information on hospital type, size,
population served, operator speciality, infrastructure, facilities and
implantation routines for their CRT device programme. The data
collected also provided useful information related to health care
resource utilisation.14
The electronic case report form
Implanting centres were asked to complete a web-based eCRF of
consecutive patients scheduled to receive a CRT device. The eCRF
collected information on patient characteristics, investigations, indica-
tions for CRT, implant procedures and short-term outcomes including
adverse events and complications during the index hospitalisation.14
Information on longer-term outcome was not collected. The eCRF
was reviewed by ESC data protection consultants to ensure patient
anonymity. This, together with the fact that the survey did not include
follow-up data after discharge, obviated the necessity for formal Insti-
tutional Review Board approval in most countries. Most centres were
simply required to notify their local or national ethics committee of
their participation in the survey.
Timelines
The first patient was included on 1 October 2015. The survey was
initially planned to run for 9months. However, the Scientific Commit-
tee decided to extend the enrolment by 6months to 31 December
2016 in order to increase sample size and improve representativeness
and therefore the ability to compare differences in practice amongst
participating countries.
Results
The CRT Survey II recruited 11 088 patients from 42 ESC coun-



















































































.. in Table 1. Using data from the EHRA White Book 2015 on
national implantation rates we estimated representativeness,17 that
is the number of patients enrolled compared with expected total
implants in that country. This metric was updated continuously
and permitted us to estimate how representative of the predicted
national implantation rates was the data collected in the survey.
Overall, the survey collected data on 11% of expected implan-
tations during the enrolment period of the survey. Of the 42 coun-
tries, 34 (81%) had >10% of the expected total number of implants
for that country.
Tables 2–6 report key findings from the total cohort and the
number of patients contributing to each data-point.
Hospital demographics
University hospitals accounted for 59% of participating centres.
The median (interquartile range, IQR) number of CRT implants
per hospital per year was 52 (30–96) and 76% of centres were
participating in a national device registry. Device remote moni-
toring was employed by 59% of centres and 99% of centres had
either partial or total reimbursement from public health providers
(Table 2).
Patient characteristics
The median (IQR) age at implantation was 70 (62–76) years, 32%
of patients were aged ≥75 years and 24% were women. Half of the
patients had ischaemic heart disease, 41% had a prior history of
AF of which 42% of these were permanent AF, 31% had diabetes
mellitus, and 47% had a HF hospitalisation during the previous year
(Table 3).
Pre-implant clinical evaluation
Most patients were in New York Heart Association (NYHA)
functional class III or IV (60%) and the natriuretic peptide levels
were generally substantially elevated. The ECG at the time of
implantation showed AF in 26%, a QRS duration of <130ms in
13% and ≥150ms in 69% of patients and 73% had left bundle
branch block (LBBB). On imaging, 13% of patients had an LVEF
>35%, the median (IQR) left ventricular end-diastolic diameter was
63 (58–69) mm and 34% had either moderate or severe mitral
regurgitation. The clinical indication for CRT implantation was HF
with a wide QRS in 60% of cases, HF or left ventricular dysfunction
and indication for an ICD in 48%. In 10% of patients the sole clinical
indication for CRTwas HF and a PPM indication with expected right
ventricular pacing dependence (Table 4).
Cardiac resynchronisation therapy
implant procedure
Hospital admission was elective for 77% of implants, 77% of which
were performed by electrophysiologists; 97% of procedures were
successful, 70% of devices implanted were CRT-D and only 25%
were referrals from other centres. The median (IQR) duration of
© 2018 The Authors
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Table 1 CRT Survey II total cohort
Country National coordinator Patients entered
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Algeria Seddik Ait-Messaoudene 66
Armenia Svetlana Grigoryan 2
Austria Marianne Gwechenberger 407
Belgium J.B. le Polain de Waroux 262
Bulgaria Svetoslav Iovev 264
Croatia Sandro Brusich 115
Czech Republic Alan Bulava 931
Denmark Helen Høgh Petersen 254
Egypt Mostafa Nawar 22
Estonia Jüri Voitk 58
Finland Sami Pakarinen 351
France Christophe Leclercq 754
Georgia Giorgi Papiashvili 24
Germany Carsten W. Israel 675
Greece Antonis Sideris 137
Hungary Gabor Duray 467
Iceland Sigfús Gizurarson 19
Ireland Ricky Sheahan 85
Israel Michael Geist 39
Italy Giovanni Luca Botto 526
Kazakhstan Roin Rekvava 34
Latvia Oskars Kalejs 79
Lebanon Marwan M. Refaat 30
Lithuania Germanas Marinskis 173
Luxembourg Laurent Groben 36
Macedonia FYR Nikola Gjorgov 70
Malta Mark Sammut 26
Montenegro Ljilja Music 6
Marocco Salima Abdelali 12
Netherlands Alexander Maass 202
Norway Torkel Steen 370
Poland Maciej Sterlinski 1241
Portugal Francisco Morgado 58
Romania Dan Dobreanu 214
Russian Federation Amiran Revishvili 71
Slovakia Peter Margitfalvi 472
Slovenia Igor Zupan 119
Spain Oscar Cano Pérez 847
Sweden Elena Sciaraffia 255
Switzerland Christian Sticherling 320
Turkey Umutay Nedim Sarigül 424
UK Chris Plummer 571
Total 11 088
the procedure was 90 (65–120) min. The right ventricular lead
was implanted first in 84% of cases and the left ventricular lead
was multipolar in 57%. The left ventricular position was evaluated
by biplane X-ray projection in 88% of patients. The left anterior
oblique site was lateral in 84% and the right anterior oblique site
was middle in 71%. The peri-procedural complication rate was 6%.
The most common complications were coronary sinus dissection,



















































































.. Table 2 Hospital demographics (n = 288)
Inhabitants of area,
median (in 100 000) (IQR) 5 (3–10)
No. of hospital beds, median (IQR) 600 (357–964)
No. of cardiology beds, median (IQR) 57 (34–80)
Type of hospital
University hospital 59% (162/274)
Teaching hospital (non-university) 23% (64/274)
Community hospital 10% (27/274)
Private hospital 8% (21/274)
CRT implantations per year, median (IQR) 52 (30–96)
Pacemaker implantations per year, median (IQR) 250 (175–400)
ICD implantations per year, median (IQR) 80 (40–132)
Cardiac surgery on site 69% (190/274)
Angiography/PCI on site 96% (262/273)
Dedicated electrophysiological labs, median (IQR) 1 (1–2)
No. of CRT implanters, median (IQR)
Electrophysiologists 2 (1–4)
Interventional cardiologists 0 (0–4)
Heart failure physicians 0 (1–2)
Follow-up
Implanting centre 93% (254/272)
Heart failure clinic 68% (186/273)
Dedicated CRT clinic 59% (161/273)
Remote device monitoring service 70% (191/272)
Centre using device monitoring by telemetry 59% (169/288)
Dedicated lead extraction/management programme 45% (123/272)
Participation in a national device registry 76% (207/273)
Use of electronic medical health records 81% (221/273)
Source of reimbursement for CRT
Public health provider 99% (270/274)
Private insurance 12% (32/274)
Private payer 7% (20/274)
In parenthesis, number of centres in each category compared to the total cohort
for each data-point.
CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter-
defibrillator; IQR, interquartile range; PCI, percutaneous coronary intervention.
Post-cardiac resynchronisation therapy
implant data
The median (IQR) hospital stay was 3 (2–7) days. In 5% of patients
an adverse event was reported and 0.4% died during the index hos-
pitalisation. Follow-up was planned at the implanting centre in 86%
of patients. Atrio-ventricular programming was performed prior to
discharge in 58% and ventriculo-ventricular programming in 56%
of patients. Device-based software was used to optimize program-
ming in 36%. HF medications at discharge included loop diuretics
(81%), beta-blockers (89%), angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II receptor blockers (ARBs) (86%) and
mineralocorticoid receptor antagonists (MRAs) (63%). Overall,
47% of patients were anticoagulated, mostly (70%) with warfarin;
10% of anticoagulated patients had no history of AF (Table 6).
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Table 3 Patient demographics (n =11 088)
Age (years), median (IQR) 70 (62–76)
Age≥ 75 years 32% (3536/11 039)
Female gender 24% (2686/11 052)
Primary HF aetiology
Ischaemic 45% (4875/10 953)
Non-ischaemic 55% (6078/10 953)
Past history and major co-morbidity
Previous myocardial infarction 36% (3957/10 926)
Prior revascularisation (PCI/CABG) 39% (4245/10 924)
Hypertension 64% (6962/10 900)
Atrial fibrillation 41% (4459/10 920)
Valvular heart disease 27% (2968/10 920)
Obstructive lung disease 12% (1315/10 922)
Diabetes 31% (3428/10 921)




Previous device (PPM or ICD) 28%(3059/10 992)
HF hospitalisation during past year 47% (5078/10 917)
Currently enrolled in a clinical trial 8% (918/11 028)
In parenthesis, number of patients in each category compared to the total cohort
for each data-point.
CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration
rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; IQR, interquar-
tile range; PCI, percutaneous coronary intervention; PPM, permanent pacemaker.
Benchmarking the top 10 recruiting
countries
Data from the 10 countries that enrolled the most patients were
compared. There were substantial differences amongst countries in
the mean age of patients implanted (Figure 1A). Symptom severity
varied substantially amongst countries (Figure 1B). The proportion
of patients with AF was about 26% with a range of 16 to 29%.
In all countries, most patients had LBBB but this ranged from
as low as 61% to 82% (Figure 1C). The percentage of patients
with a QRS duration <130ms ranged from 7% to 19% but most
patients had a QRS duration >150ms (Figure 1D). The percentage
of patients upgraded from another device was between 21% and
39% (Figure 1E) and those receiving a CRT-P ranged from 2% to 37%
(Figure 1F). The median duration of hospitalisation varied markedly
(Figure 1G), with a median of 3 days.
Discussion
This second, larger survey of CRT implantations in ESC member
countries provides a valuable source of clinical information describ-
ing ‘who is doing what to whom and how’, permits benchmarking
across Europe and provides essential feedback on guideline adher-
ence, which supports the development of future guidelines.
The ‘Who’ are implanters, and as expected, primarily electro-
physiologists, although a considerable number of implanters are not
(23%). The ‘What’ are primarily CRT-D devices (70%) but in many
countries up to 40% of implants are CRT-P devices. The ‘Whom’




















































































Table 4 Pre-implant clinical evaluation (n =11 088)
NYHA class
I 3% (370/10 848)
II 38% (4083/10 848)
III 55% (5909/10 848)
IV 5% (486/10 848)
BMI (kg/m2), median (IQR) 27 (25–31)
Systolic blood pressure (mmHg), median
(IQR)
122 (110–137)
Diastolic blood pressure (mmHg), median
(IQR)
72 (66–80)
Laboratory measurement (most recent),
median (IQR)
BNP (ng/L) 422 (150–1115)
NT-proBNP (ng/L) 2400 (1049–5517)
Serum creatinine (𝜇mol/L) 100 (83–129)
Haemoglobin (g/dL) 13 (12–15)
Pre-implant ECG
Heart rate (b.p.m.), median (IQR) 70 (60–80)
Atrial rhythm
Sinus 69% (7496/10 836)
Atrial fibrillation 26% (2778/10 836)
Atrial paced 3% (303/10 836)
Other 2% (259/10 836)
PR interval (ms), median (IQR) 180 (160–210)
AV block II/III 19% (2026/10 700)
Pacemaker dependent 14% (1511/10 752)
Intrinsic QRS morphology
LBBB 73% (7861/10 800)
Non-LBBB 27% (2939/10 800)






Clinical indication for CRT
HF with wide QRS 60% (6550/10 923)
HF or LV dysfunction and indication for
ICD
48% (5228/10 923)
PM indication and expected RV pacing
dependence
23% (2494/10 923)
Evidence of mechanical dyssynchrony 12% (1260/10 923)
Other 5% (487/10 923)
LVEF (%), median (IQR) 29 (23–34)
<25 28% (2979/10 805)
25–35 60% (6426/10 805)
>35 13% (1400/10 805)
LVEDD (mm), median (IQR) 63 (58–69)
Mitral regurgitation
Mild 46% (4644/10 000)
Moderate 27% (2646/10 000)
Severe 7% (690/10 000)
None 20% (2020/10 000)
Note: total can be ≥100% due to rounding off. In parenthesis, number of patients
in each category compared to the total cohort for each data-point.
AV, atrio-ventricular; BMI, body mass index; BNP, brain natriuretic peptide;
CRT, cardiac resynchronisation therapy; ECG, electrocardiogram; HF, heart
failure; ICD, implantable cardioverter-defibrillator; IQR, interquartile range;
LBBB, left bundle branch block; LV, left ventricular; LVEDD, left ventricular
end-diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association;
PM, pacemaker; RV, right ventricular.
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Table 5 Cardiac resynchronisation therapy
implantation procedure (n =11 088)
Elective admission 77% (8422/10 946)
Referral from another centre 25% (2770/10 938)
Admission to implantation time (days),
median (IQR)
1 (1–4)
Successful implantation 97% (10 798/11 100)
Unsuccessful implantation 3% (302/11 100)
No. of attempts per patient
One attempt per patient 99% (10 971/11 088)
Two attempts per patient 1% (106/11 088)
Three attempts per patient <1% (11/11 088)
Type of device
CRT-P 30% (3256/10 769)
CRT-D 70% (7513/10 769)
Operator
Electrophysiologist 77% (8302/10 779)
HF physician 5% (541/10 779)
Invasive cardiologist 12% (1330/10 779)
Surgeon 4% (464/10 779)
Other 1% (142/10 779)
Duration of procedure (min), median (IQR) 90 (65–120)
Fluoroscopy time (min), median (IQR) 14 (8–22)
Prophylactic antibiotics 99% (10 527/10 672)
Which lead was implanted first
RV 84% (8816/10 555)
LV 16% (1733/10 555)
RV lead placement
Apex 61% (6280/10 253)
Septum 36% (3733/10 253)
RVOT 2% (240/10 253)
LV lead placement successful 99% (10 533/10 594)
LV lead type
Unipolar 1% (77/10601)
Bipolar 42% (4478/10 601)
Multipolar 57% (6046/10 601)
Coronary venogram performed 92% (9636/10 529)
Venogram performed with occlusion 47% (4486/9522)
Dilatation of coronary vein performed 2% (251/10 538)
Phrenic nerve stimulation tested 90% (9556/10 568)
LV lead position evaluation 97% (9943/10 302)
Biplane X-ray projection 88% (8771/9943)
Monoplane LAO 11% (1105/9943)
Monoplane RAO 1% (67/9943)
LAO site
Lateral 84% (8665/10 300)
Posterior 12% (1188/10 300)
Anterior 4% (447/10 300)
RAO site
Middle 71% (7200/10 119)
Basal 15% (1505/10 119)
Apical 14% (1414/10 119)
LV position optimized 34% (3484/10 307)
Peri-procedural complications 6% (624/11 088)
Death 0.1% (8/11 088)
Bleeding 1.0% (108/11 088)




















































































.. Table 5 Continued
Pocket haematoma 0.8% (85/11 088)
Pneumothorax 1.0% (112/11 088)
Haemothorax 0.1% (9/11 088)
Coronary sinus dissection 1.9% (214/11 088)
Pericardial tamponade 0.3% (28/11 088)
Other 1.6% (172/11 088)
Note: total can be ≥100% due to rounding off. In parenthesis, we indicated the
number of patients in each category compared to the total cohort for each
data-point.
CRT, cardiac resynchronisation therapy; D, defibrillator; HF, heart failure; IQR,
interquartile range; LAO, left anterior oblique; LV, left ventricular; P, pacemaker;
RAO, right anterior oblique; RV, right ventricular; RVOT, right ventricular outflow
tract.
<75 years, with an LVEF <35%, in sinus rhythm, with LBBB and a
QRS duration ≥150ms. The ‘How’ reveals that most implantations
are elective with a low peri-procedural mortality (<1%). Referrals
from non-implanting centres accounted for only 25%, indicating
that patients outside university or teaching hospital settings have
limited access to CRT. The Swedish HF Registry, which included
12 807 patients, demonstrated that underutilisation was associated
with demographic, organizational and socio-economic characteris-
tics as well as clinical information. For example, the likelihood of
being considered for CRT was much higher if the patients were
managed by cardiologists rather than other specialists or primary
care physicians.18
An excellent overview of the diverse issues that serve to explain
why only about one-third of CRT candidates are actually implanted
with a device has recently been published.19 CRT Survey II also
confirms that clinicians continue to extrapolate data from RCTs
to patients who are not well represented in the evidence base.
Clinical practice may be guided by clinical trials but differences in
practice exist because clinicians have accumulated experience and
try to offer the best treatment to individual patients, many of whom
do not fulfil the selection criteria for the RCTs. Many devices were
implanted in patients with AF or relatively narrow QRS complexes,
or requiring a device upgrade. In these patient groups, guidelines
either contraindicate CRT or make only weak recommendations.
Compared to patients enrolled in RCTs, patients in this survey
were generally older, had more co-morbidities, were less likely
to have ischaemic heart disease, had higher LVEF, narrower QRS
complexes and more AF but a similar proportion were women.20
Compared to men, the low number of women receiving CRT
is of concern. Women with HF with reduced ejection fraction
(HFrEF) are more likely to have LBBB and may benefit from CRT
at a shorter QRS duration than men.21,22 However, women with
HF are older and less likely to have a reduced LVEF.23 Accordingly,
the low number of women receiving CRT may reflect the relatively
lower number of women aged <75 years with HFrEF rather than a
lower proportion of such women who are eligible for CRT.
CRT implants were upgrades from a previous PPM or ICD
device in 28% of procedures. The landmark trials of CRT, with the
exception of RAFT, excluded patients with a prior device. In RAFT,
an upgrade from an ICD or PPM was not associated with benefit.7
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Table 6 Post-cardiac resynchronisation therapy
implantation (n =11 088)
Post-implant ECG
Paced QRS duration (ms), median (IQR) 137 (120–151)
Device programming
AV programming performed prior to
discharge
58% (6132/10 593)
VV programming performed prior to
discharge
56% (5962/10 577)




Alive 99.6% (10 801/10 845)
Dead 0.4% (45/10 845)
Total length of hospital stay (days), median
(IQR)
3 (2–7)
Major adverse events after implantation 5% (528/11 088)
Myocardial infarction 0.1% (8/10 816)
Stroke 0.1% (6/10 816)
Infection 0.6% (60/10 816)
Worsening heart failure 0.7% (78/10 816)
Worsening renal function 1.0% (104/10 816)
Arrhythmias 1.2% (128/10 816)
Other 1.9% (208/10 816)
Planned follow-up
Implanting centre 86% (9345/10 818)
Other hospital 8% (873/10 818)
Cardiologist in private practice 5% (569/10 818)
Primary care physician 1% (92/10 818)
CRT/pacemaker clinic 10% (1124/10 818)
Heart failure management clinic 3% (273/10 818)
Other 0% (34/10 818)
Drug therapy at discharge
Loop diuretic 81% (8621/10 635)
ACE inhibitor/ARB 86% (9163/10 603)
MRA (aldosterone antagonist) 63% (6682/10 573)
Beta-blocker 89% (9472/10 648)
Ivabradine 6% (593/10 543)
Digoxin 10% (1100/10 544)
Calcium channel blocker 9% (946/10 531)
Amiodarone 17% (1825/10 547)
Other anti-arrhythmic agent 2% (181/10 531)
Oral anticoagulant 47% (4928/10 577)
Warfarin (coumadin) 33% (3463/10 577)
Dabigatran 3% (327/10 577)
Rivaroxaban 6% (611/10 577)
Apixaban 5% (509/10 577)
Edoxaban <1% (18/10 577)
Anti-platelet agent 44% (4846/11 088)
Aspirin 41% (4357/10 547)
Clopidogrel 12% (1304/10 547)
Ticagrelor 1% (136/10 547)
Prasugrel <1% (31/10 547)
In parenthesis, number of patients in each category compared to the total cohort
for each data-point.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; AV,
atrio-ventricular; CRT, cardiac resynchronisation therapy; ECG, electrocardio-





















































































.. Accordingly, the 2012 ESC guidelines do not provide guidance on
upgrades. Although the 2013 ESC EHRA guidelines provided a class
I recommendation and level of evidence B for device upgrade for
patients with persistent symptoms compatible with HF,9 the 2016
ESC guidelines offered only a class IIb recommendation.8 Although
pacing generally prolongs QRS duration, its clinical significance with
respect to CRT may differ. The importance of atrio-ventricular
resynchronisation may be as or more important than bi-ventricular
resynchronisation and the benefit of upgrading devices to CRT is
not well established.
The rhythm at implantation was AF for 26% patients in this
survey. The 2013 EHRA and 2012 and 2016 HFA guidelines
provide either a IIa or IIb recommendation for patients with AF
but emphasise the importance of pharmacological rate control
or atrio-ventricular nodal ablation in order to adequately ensure
bi-ventricular capture.8,9,12 No substantial trial has compared
CRT to a pharmacological control group for patients with AF.
A subgroup of patients in the RAFT study had AF and did not
appear to benefit, which was ascribed to inadequate ventricular
capture.7 Similarly, a recent report from COMPANION also
suggested that patients with a prior history of AF did not benefit
from CRT, although incident AF did not appear to reduce benefit
in CARE-HF.4,24 At least two trials have compared CRT to right
ventricular pacing after atrio-ventricular node ablation. These
suggest that CRT is superior.25,26 However, whether this reflects a
benefit from CRT or simply avoiding the harm of right ventricular
pacing is unclear. For this reason, some experts think that current
guidelines provide an unduly strong recommendation for CRT in
patients with AF.
This survey shows that 8% of implants were in patients with
a QRS <120ms and that a further 5% had a QRS duration
120–129ms. The 2012 HFA guidelines recommended CRT
implantation only when QRS duration was >120ms in the pres-
ence of more severe symptoms and LBBB or QRS >130ms
when symptoms were mild and LBBB was present or when QRS
duration was >150ms in the absence of LBBB.12 In May 2016 the
most recent version of the HFA guidelines, based on the results of
EchoCRT and an individual-patient data meta-analysis, suggested
that CRT is contraindicated when QRS duration is <130ms.8,27–29
This survey ran from October 2015 to December 2016. Future
analyses will determine whether practice evolved over the course
of the survey.9,12 Of note, the median QRS duration was nar-
rower (144ms compared with 160ms) for patients implanted
only for the clinical indication ‘PM indicated and expected right
ventricular pacing dependence’ compared to the overall cohort.
A total of 10% of the survey population were implanted with
only this clinical indication and 22% of this group had a QRS
duration <120ms. However, most patients in this survey had a
QRS duration ≥150ms. Individual-patient data meta-analyses of
RCTs have convincingly shown that longer QRS durations predict
greater long-term benefit from CRT.28,30
Patients in this survey were generally treated with loop diuretics
(81%), ACE inhibitors/ARBs (86%), beta-blockers (89%), and MRAs
(63%) at discharge from hospital. Guidelines recommend implan-
tation of CRT only after patients have been optimally medically
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A Age
B NYHA Functional Class
Figure 1 Legend on next page.
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Left Bundle Branch BlockC
Intrinsic QRSD
Figure 1 Legend on next page.
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Type of DeviceF
Upgrade from Previous DeviceE
Figure 1 Legend on next page.
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Length of Hospital StayG
Figure 1 The figure presents a comparison of selected characteristics across the top 10 recruiting countries. (A) Age of patients implanted
with cardiac resynchronisation therapy (CRT) devices. (B) New York Heart Association (NYHA) classification. (C) QRS morphology on
pre-implant electrocardiogram. (D) QRS duration on pre-implant electrocardiogram. (E) Upgrades to CRT from previous device (permanent
pacemaker or implantable cardioverter-defibrillator). (F) Type of device implanted (CRT-P vs. CRT-D). (G) Length of hospital stay. Asterisks
demonstrate the level of statistical significance of the bottom red category for each country as compared to the total cohort. One asterisk
denotes a P-value of <0.01 and two asterisks a P-value of <0.001.
managed. Although the proportion of patients in the survey dis-
charged on disease-modifying medications is less than ideal and less
than observed in some registries, it is still similar or greater than
observed in most of the landmark clinical trials that proved the
efficacy of CRT, many other registries or in clinical practice.18,31
The process of developing evidence-based guidelines includes
both adequate evaluation by randomised clinical trials as well as
feedback from surveys and registries. Survey and registries demon-
strate the degree to which guidelines are adopted in practice.
Therefore, the extensive observational data that we have collected
highlight which guideline recommendations are or are not being
adhered to as well as how physicians extrapolate existing data to
clinical challenges they encounter in practice where evidence is
lacking. These gaps in evidence are intentionally included in all ESC
guidelines in order to identify potentially fruitful area for future
research.
The one-time site questionnaire includes information such as
total number of beds per hospital, type of hospital, number of
CRT devices implanted annually and the number and speciality of
implanters, which provides valuable information related to health
care resource demands and capacity. A dedicated health care
































. The data selected for benchmarking are directly related to
patient selection, clinical practice and health care resource utili-
sation in the top 10 recruiting countries. Benchmarking of these
countries in the survey revealed remarkable similarities with regard
to patient selection. However, there were also many highly signifi-
cant differences between countries (Figure 1), especially the popu-
lations aged ≥75 years with QRS <130ms, NYHA class III or IV as
well as choice of device (CRT-P vs. CRT-D).
Particularly striking was the difference in index hospitalisation
duration between the top 10 countries. Hospitalisation for implan-
tation of a CRT can facilitate initiation and up-titration of optimal
medical therapy, which can prolong hospital stay. Differences in
the length of hospital stay depend both on the implanting cen-
tre and the collaboration with the outpatient HF services. Some
of the observed differences in these countries’ CRT implantation
practice will be related to the country’s economic strength, the
proportion of their budget allocated to health care and the demo-
graphics of the population. The initial cost of CRT is substantial
due to the device itself, the implantation procedure, hospitalisation
and follow-up. However, the symptomatic improvement following
CRT and the reduction in HF hospitalisation makes it an effective
use of resources. Countries with limited financial resources may
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select patients most likely to respond and also may prefer CRT-P
to CRT-D due to the reduced cost. In Europe, physicians may be
more willing to extrapolate beyond the existing evidence and guide-
lines for CRT because the risk of medical litigation is relatively low.
Most procedures are funded partly or entirely by public funding
and there is limited formal audit of adherence to guidelines.
Limitations
The strength and ability of a survey to address questions are
related to the strength of its methodology, its representativeness
and size. Although the number of patients enrolled in this survey
was large, there were substantial differences amongst countries.
Overall, we estimate that about 11% of patients implanted with
CRT in participating countries were enrolled in the survey. We
cannot assess the degree of selection bias in the choice of enrolled
patients. Sites may have been less likely to report unsuccessful
implants or cases with a poor outcome, accounting for low compli-
cation and mortality rates. The number of implanting sites ranged
from 1 to 37. In countries with few participating centres, these
centres’ practice will have a great impact on the national results.
The eCRF was designed to be as user-friendly as possible in
order to maximise the number of patients enrolled. Unavailable
patient data could be omitted; the analyses were based on the
available data, which explains the variation in the sample size for
each data point. Furthermore, the interpretation of questions was
up to the discretion of the investigator. Although there was no
formal independent monitoring of the data collection, the IHF
conducted ‘front-end’ data check and post database lock quality
control analyses designed to prevent incorrect data being analysed.
The most recent ESC HF guidelines were released during the
enrolment period of the survey.8 It requires time before new
guidelines are adopted into evolving clinical practice. It is difficult
to quantify the effect that this had on the selection and enrolment
of patients subsequent to the release of the most recent ESC
guidelines.
Conclusion
CRT Survey II provides a valuable source of information on contem-
porary clinical practice with respect to CRT implantation in a large
sample of ESC member states. The survey demonstrates important
similarities as well as substantial differences in patient selection,
implantation procedure and follow-up. The data collected are
sufficient to permit meaningful benchmarking between the high-
est recruiting countries and for assessing guideline adherence
and health care resource utilisation. This should assist in educa-
tional initiatives and identifying appropriate directions for future
research.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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